Vol. 24 No. 2 • June 2025

Promoting Cardiovascular Education, Research and Prevention

CV Network

THE OFFICIAL BULLETIN OF THE INTERNATIONAL ACADEMY OF CARDIOVASCULAR SCIENCES

PUBLISHED WITH THE ASSISTANCE OF THE ST. BONIFACE HOSPITAL ALBRECHTSEN RESEARCH CENTRE

In this Issue

Dr. Roberto Bolli Receives Honorary Doctor of Science from "Victor Babeş" University of Medicine and Pharmacy, Romania

Dr. Bolli (L) presented with Honorary D.Sc. from Vice Rector Dr. Daniel Lighezan

Prof. Roberto Bolli has been awarded the title of Doctor Honoris Causa (DHC) by "Victor Babes" University of Medicine and Pharmacy in Timişoara, Romania. This decision was made by the Senate of the University, upon recommendation of the Council of Administration, in recognition of Prof. Bolli's prestigious academic, scientific and professional achievements in the field of cardiovascular research. The award ceremony took place on May 12, 2025, in the Senate Hall, and was presided by Prof. Daniel Lighezan, Vice Rector for Education, and attended by Prof. Danina Muntean, Chair of Pathophysiology, Faculty of Medicine. Prof. Bolli delivered a lecture on cell-based therapies for heart disease and another lecture targeted at students/junior faculty with advice for pursuing an academic career. This is the second Doctor Honoris Causa award bestowed to Prof. Bolli, the first being from the University of Kragujevac, Serbia. The Academy extends its heartiest congratulations to Prof. Bolli for this high honor. Dr. Bolli is Past President of the IACS and has received numerous awards worldwide. He is currently, Professor of Medicine, Physiology and Biophysics, University of Louisville, School of Medicine, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology, Director, Institute of Molecular Cardiology and Distinguished University Scholar. From his webpage in the University website, Dr. Bolli declared his philosophy as: *"My clinical focus has been to look beyond the "bread-and-butter" treatment options, particularly in patients who have little or no hope. I strive to provide the latest, cutting-edge clinical care expected in a top-tier university setting in hopes that I can be of service to all patients, but a proclivity toward those who have run out of conventional options."*

Academy Pays High Tribute to Dr. Gary Lopaschuk

Jason Dyck
Professor, Department of Pediatrics, Canada Research Chair in Molecular Medicine
Director, Cardiovascular Research Centre, Co-Director, Alberta HEART
University of Alberta, Edmonton, Alberta, Canada
Corresponding email: jrbdyck@ualberta.ca

Dr. Gary Lopaschuk
(1955-2025)

On April 2, 2025, the scientific and academic community experienced a tremendous loss with the sudden passing of Dr. Gary Lopaschuk.

Gary's journey in science began with a BSc in Pharmacy from the University of British Columbia, followed by an MSc in Pharmacology and Toxicology under the mentorship of Dr. S. Katz. Gary continued his doctoral work at UBC, completing a PhD under the guidance of Drs. J.H. McNeill and S. Katz. After his PhD, Gary pursued post-doctoral research at the Milton S. Hershey Medical Center in Pennsylvania, under the mentorship of Dr. J.R. Neely—an experience that would shape the trajectory of his lifelong focus on cardiac energy metabolism.

Gary started his independent career at The Hospital for Sick Children at the University of Toronto as a member of the newly formed Cardiovascular Group (1985-1986) affiliated with the Departments of Pediatrics and Pharmacology. He then relocated to Alberta in 1986 to join the Department of Pediatrics at the University of Alberta, where his scientific career flourished. In recognition of his outstanding contributions to research and teaching, he was named a Distinguished University Professor in 2010—a title he held with pride for the remainder of his career. In 2020, Gary was also awarded the University Cup, which is considered the highest honor the University of Alberta can bestow upon a member of its academic staff for research excellence, mentorship, and service to the University and the community. Until his final day, Gary remained deeply committed to his work, driven by the same passion that defined his entire professional life.

Gary's name is synonymous with the field of cardiac energy metabolism. His discoveries and contributions to the field help demonstrate that alterations in cardiac energy metabolism could be major contributors to conditions such as heart failure, ischemia/reperfusion injury, and diabetic cardiomyopathy. Impressively, Gary began his research on this topic at a time when metabolism was not recognized as having a major contribution to cardiovascular disease. However, Gary dedicated most of his career proving that cardiac metabolism mattered, and his work helped shape the field. His research also helped position the University of Alberta as a global leader in this area. This will remain a lasting part of Gary's legacy.

Another hallmark of Gary's scientific excellence was his tremendous grasp of the literature. He possessed an encyclopedic knowledge of both current research and the foundational studies that shaped the field. Most impressively, he could readily quote decades-old papers, drawing connections across time that assisted his own work and increased the insights of those around him. This deep understanding and appreciation for the field's history likely contributed to his vision for how best to move it forward.

Over the years, Gary was the recipient of numerous honors and awards and was regularly invited to speak at prestigious international conferences. He was an enthusiastic speaker, with a talent for making even the most complex metabolic pathways engaging and easy to understand. Sitting in the audience, one could feel Gary's passion for science, and it was evident that he used these opportunities not just to share his own work, but to advance the entire field. Just as importantly, Gary didn't simply present and leave; he always stayed to listen. He was a fixture in the audience at conferences, and almost every talk he attended ended with Gary making his way to the microphone to ask a thoughtful question. His enthusiasm for discovery, even when the spotlight wasn't on him, was a true testament to his dedication and humility.

Gary's contributions to advancing his field didn't end with research; they also included his deep commitment to mentoring. He mentored and inspired countless graduate students, postdoctoral fellows, and early-career faculty across multiple generations. He was always generous with his time, offered insightful and constructive feedback, and genuinely wanted his trainees to succeed—not to advance his own interests, but because he truly cared about helping them build their careers. In the days following Gary's passing, numerous messages from his former trainees around the world poured in, expressing the profound loss they felt. This sense of sadness extended to colleagues who had worked with Gary or met him through grant review panels or at conferences. He will be deeply missed by many—not only for his remarkable contributions as a scientist, but also for the profound impact he had as a truly kind and generous person.

In remembering Dr. Gary Lopaschuk, we honor a scientist of exceptional passion, a mentor of uncommon generosity, and a friend whose presence will be deeply missed. Although Gary's absence will be felt by many, his impact will remain in the field he helped pioneer, the papers he published, and the careers he launched.

Dr. Grant Pierce, President of the IACS stated "*Scientifically speaking, Dr. Gary Lopaschuk and I grew up together. Although we were always in different labs, he and I had similar research directions early in our careers and we always met each year. Every year, I would meet Gary several times all over the world - at ISHR and IACS conferences, and at grant review panels for the Heart and Stroke Foundation of Canada, Medical Research Council of Canada and the Canadian Institutes of Health Research. I grew to know Gary very well. He was an outstanding researcher, an innovative pioneer in science, he got along socially with everyone and he was a very good friend not only to me but to many, many colleagues. He was brilliant, always followed enviable ethical conduct in all of his actions and he became, without a doubt, the preeminent scholar on human metabolism in the entire world. By the end of his career, Dr. Gary Lopaschuk simply had no peer in the field of metabolism. I will miss his insights and the fun we had together for over 40 years. Most importantly, in recent years Gary was still enjoying research and would have undoubtedly made additional discoveries that the world will also miss. Safe travels Gary! The world will miss your smile and your significant contributions!*"

IACS Honors and Awards at the 12th IACS-North American Section Meeting in Las Vegas, USA

The Academy is pleased to announce that the following IACS honours and awards will be bestowed upon individuals during the 12th IACS- North American Section Meeting, September 18-20, 2025 in Las Vegas, USA.

1. **IACS Medal of Merit**- *Dr. Grant Pierce*
2. **Naranjan Dhalla Award for Innovative Investigators in Cardiovascular Science**- *Dr. E. Douglas Lewandowski*
3. **Grant Pierce Award for Excellence in Cardiovascular Sciences**- *Dr. Vladimir Jakovljevic*
4. **James Willerson Award for Excellence in Cardiovascular Medicine**- *Dr. Jagat Narula*
5. **Howard Morgan Award for Distinguished Achievements in Cardiovascular Research-** *Dr. Ali J. Marian*
6. **Jay Mehta Award for Clinical Scientist**- *Dr. Petr. Ostadal*
7. **Paul Ganguly Distinguished Lecture Award in Cardiovascular Sciences**- *Dr. Ravichandran Ramasamy*
8. **Amarjit Arneja Distinguished Lecture Award in Prevention of Heart Disease**- *Dr. Jianyi "Jay" Zhang*
9. **Suresh Tyagi Award for Excellence in Cardiovascular Sciences**- *Dr. Maria L. Kontaridis*

Dr. Grant Pierce to Receive IACS Medal of Merit



Dr. Grant Pierce

A. Academic Career

Grant N. Pierce received his undergraduate degree from Lakehead University in Thunder Bay, Canada before being awarded his MSc from Dalhousie University in Halifax, Canada under the directions of Drs Angelo Belcastro and Arend Bonen. He received his PhD from the Department of Physiology at the University of Manitoba under the supervision of Dr. Naranjan Dhalla. After postdoctoral studies at UCLA under the mentorship of Drs. Ken Philipson and Glenn Langer, he returned to the University of Manitoba to assume a faculty position in Medicine and the Department of Physiology where he ultimately became a Distinguished Professor. Along that journey, Dr Pierce was one of 5 Professors who together created the Albrechtsen Research Centre at St Boniface Hospital in Winnipeg, Canada. It became a world class research home for Dr Pierce for the next 38 years. For 15 of those years, Dr. Pierce served as its Executive Director of Research. There he established the Canadian Centre for Agri-food Research in Health and Medicine (CCARM) which has become an internationally recognized resource in nutraceutical and functional food research excellence for both basic science and clinical trials. He also established the RBC Youth BioLab in the Research Centre, a one-of-a-kind lab for children who visit daily throughout the year to carry out educational experiments in biology. Dr. Pierce is currently a Distinguished Emeritus Professor at the University of Manitoba.

B. Research Accomplishments

Dr. Pierce has been highly productive over his career with 300+ published research papers, over 260 of these were peer reviewed in some of the top cardiovascular (CV), nutritional, biochemistry & cell biology journals including Circulation Research, the Journal of Molecular and Cellular Cardiology, Cardiovascular Research, the American Journal of Physiology, the Journal of Biological Chemistry, the Journal of Cell Biology, the Journal of Nutrition, the Proceedings of the National Academy of Sciences USA, Pharmacology Reviews, and many others. He has authored or edited 8 textbooks. He has >11,500 citations, a Google Scholar H-index of 67 and an i10-index of 208. Dr. Pierce has produced many seminal research findings during his career.

These include (in chronological order):

1) Pioneered research in the identification of a diabetic cardiomyopathy when this concept was not accepted in the late 1970's/early 80's. It is now a well-accepted concept with clinical implications.

2) Pioneered research into the mechanism responsible for ischemic/reperfusion (I/R) injury in the heart. One of three labs in the world that initially proved that the involvement of a Na/H and Na/Ca exchange cascade is critical for I/R injury.

3) First to show a cause-and-effect relationship between Chlamydia pneumonia infection and atherosclerosis.

4) Currently a leader in the health-related benefits of natural health products. He has provided seminal data on the beneficial cardiovascular actions of dietary flaxseed.

5) Dr. Pierce pioneered the measurement of nuclear protein import in cardiovascular cells and how it can adapt to changing physical and chemical conditions inside and outside of the cell. This transport across the nuclear membrane is important because it effectively regulates gene transcription and translation and it may be critically involved in pathogenic situations. It is, therefore, a novel target for therapeutic interventions in the future.

6) Dr. Pierce, in collaboration with Drs. Pavel & Elena Dibrov, discovered a novel antibiotic compound that targets bacterial energy metabolism, the first novel antibiotic platform in half a century. This compound has the potential to avoid the challenge of multi-drug resistance exhibited by most bacteria today.

Dr. Pierce has been the Primary Supervisor for 25 PhD & MSc students, as well as 17 postdocs and visiting scientists who have gone on to successful careers and leadership roles as University Professors, Department Chairs, Clinicians and Surgeons, Clinical Directors, Research Directors, Clinical Research Scientists, Senior Managers in the pharmaceutical industry, Project Managers, Technology Transfer Managers, Physician Assistants, Clinical Physiotherapists, Directors of Regulatory Affairs, Health Canada Senior Compliance Officers, Research Facilitators, medical students and postdoctoral fellows in Canada, France, Germany, Japan, Cuba, Argentina and the USA. His postdoctoral fellows have gone on to successful faculty positions in Canada, Japan, France, Lebanon and the Czech Republic, positions in industry and many have become physicians.

C. Service

Dr. Pierce was the longest serving Editor that the Canadian Journal of Physiology and Pharmacology has ever had since its inception in 1964. He was the Assistant/Associate Editor of Molecular and Cellular Biochemistry for over 30 years. He has been a member of Editorial Boards for Circulation Research, Journal of Molecular and Cellular Cardiology, American Journal of Physiology:Heart and Circulatory Physiology, and the Canadian Journal of Cardiology, amongst others. Dr. Pierce has served as an elected member of the Executive Council for the North American Section of the International Society for Heart Research, President of the North American Section of the International Academy of Cardiovascular Sciences and is its current World President. Dr. Pierce has been involved in the organization of more than 90 international meetings and been an invited speaker on his own data at over 200 national and international conferences as well as 175 University & public forums. Dr. Pierce served as a member, Vice Chair or Chairperson of 90 different grant review panels all over the globe. For three years, he was Chair of the Executive Review Committee for the Heart and Stroke Foundation of Canada where he oversaw all peer review.

D. Awards and Distinctions

Dr. Pierce's research has brought garnered over 100 personal awards and distinctions from 9 different countries. Several deserve attention here. Dr Pierce was an elected Fellow of the American College of Cardiology, the American Heart Association, the American Physiological Society, the International Society for Heart Research, the International Academy of Cardiovascular Sciences, the Canadian Academy of Health Sciences, and the Royal Society of Medicine (London). Dr. Pierce was inducted as a Fellow into the Royal Society of Canada. Induction into the Royal Society of Canada "represents Canadian scholars, artists, and scientists, peer-elected as the best in their field… from all branches of learning who have made remarkable contributions in the arts, the humanities and the sciences, as well as in Canadian public life." Dr. Pierce received the Queen Elizabeth II Diamond Jubilee Medal from the Government of Canada and the 2016 Research Canada Leadership Award. Dr. Pierce was invested with the Order of Manitoba, the Province of Manitoba's highest honour which recognizes citizens who have achieved excellence thereby enriching the social, cultural or economic well-being of the province. In 2023, he received the Order of Canada, the highest distinction for a citizen in Canada. Presented by the governor general, it recognizes "outstanding achievement, dedication to the community and service to the nation of Canada".

Dr. E. Douglas Lewandowski, Columbus, USA

Dr. E. Douglas Lewandowski

Dr. E. Douglas (Doug) Lewandowski, Ph.D. is a Professor and Jack George Chair in Medicine in the Department of Internal Medicine at the Ohio State University (OSU) College of Medicine in Columbus, OH, with joint appointments in the Division of Endocrinology, Diabetes, & Metabolism and the Division of Cardiovascular Medicine. Dr. Lewandowski is internationally recognized as an expert in cardiac metabolism and the metabolic basis of impaired cardiac function in heart disease. His most current research focuses on targeting mechanisms of adverse metabolic remodeling in early heart failure and the reciprocal metabolic cross talk between the heart and other organs during the progression of cardiac disease. A pioneer in the evaluation of metabolic rates in functioning organs using stable isotope kinetics and nuclear magnetic resonance detection schemes, he is a recipient of a MERIT Award (R37) from the National Heart, Lung and Blood Institute of the NIH and an Established Investigator Award from the American Heart Association. He is also a recent recipient of the Research Achievement Award from the International Society for Heart Research (ISHR) and the Bernard and Joan Marshall Distinguished Investigator Award from the British Society for Cardiovascular Research.

His first faculty appointment was in the Section of Cardiology, Department of Medicine at the Baylor College of Medicine (BCM) in Houston, TX where he explored the metabolic basis of contractile dysfunction in postischemic hearts. After being recruited to Harvard University Medical School and Massachusetts General Hospital in Boston, MA, in the Department of Radiology and the Division of Cardiology, Department of Medicine, he established ^{13}C NMR methods to detect TCA cycle flux and quantify rates of metabolite transport across the mitochondrial membrane in intact hearts. This lead to a series of studies on metabolic communication between the cytosol and the mitochondrial matrix via malate aspartate shuttle flux in normal and diseased hearts. His novel approaches for ^{13}C NMR studies have had broad impact and have been adopted for NMR measures of metabolic flux in the brain. At that time, Doug also began a long collaboration with Steven Vatner MD, who was at Harvard's Brigham and Women's Hospital, exploring the metabolism of hypoperfused myocardium due to coronary stenosis in *in vivo* hearts in large animal models.

Doug later joined the University of Illinois School of Medicine at Chicago as a Professor in the Department of Physiology and Biophysics and the Division of Cardiology, Department of Medicine. He was the Director of the Center for Cardiovascular Research, served as Interim Head of the Department of Physiology and Biophysics, and was named a University of Illinois Scholar, conferred by the President of the University System. At UIC he began work on gene delivery schemes for metabolic enzyme expression and suppression as therapeutics to reduced adverse pathological remodeling of the heart, which extends to his current research activities.

His other work led to the realization that triglyceride turnover is a key source fuel for ATP production and importantly, of ligands activating PPAR-alpha, and that diminished triglyceride turnover in failing hearts was linked to impaired PPAR-alpha target gene expression. He also established ^{13}C NMR based detection of the rates of transporter dependent fatty acid entry into the cardiomyocytes of functioning, normal and diseased hearts and the combined use of MRS of cardiac triglyceride content with ultra-high field, high resolution cardiac tagged MRI measures of transmural strains across the ventricular wall of the *in vivo* mouse heart. His current work also explores the consequences of congestive heart failure on the peripheral organ metabolism and whole body metabolic health.

Dr. Lewandowski is a Fellow of the ISHR (FISHR), the American Association for the Advancement of Science (AAAS), the American Heart Association (FAHA), and the American Physiological Society Cardiovascular Section. He was the inaugural Young Investigator Awardee from the Society of Magnetic Resonance in Medicine (later renamed the International Society of Magnetic Resonance in Medicine).

He serves on the Editorial Boards of *Circulation* and *Circulation Research*, and is a Senior Consulting Editor for the *Journal of Molecular and Cellular Cardiology (JMCC)*, with past editorial board appointments on the *American Journal of Physiology* and *Frontiers in Fatty acid and Lipid Physiology*. He has served as a fulltime member of two NIH study sections and multiple *ad hoc* assignments, and chaired numerous NIH Special Emphasis Panel review groups.

His former students and postdoctoral trainees have gone on to become basic scientists and physician scientists at Medical Schools and Universities, Pharmaceutical Companies, and Industry. His vibrant research group is always looking to welcome graduate student and postdoctoral candidates who share a passion for discovering novel mechanisms of metabolic flux regulation and an interest in state-of-the-art approaches for exploring cardiac metabolism and identifying disease mechanisms as potential therapeutic targets in the battle against heart disease.

Dr. Vladimir Jakovljevic, Kragujevac, Serbia

Dr. Vladimir Jakovljevic

Dr. Vladimir Jakovljevic, Professor and Head of Cardiovascular Research Laboratory, Faculty of Medical Sciences University of Kragujevac, Serbia. After more than 20 years of research experience, Dr. Jakovljevic is a leading scientist in the field of cardiovascular science in Serbia and this part of the World, with more than 160 papers in journals indexed in Science Citation Index list. Dr. Jakovljevic finished PhD thesis in 2004 and specialization in Clinical Physiology in 2005 in University of Belgrade. His main research interests represent examination of the changes in the cardiovascular system in various pathophysiological conditions and role of oxidative stress and reactive species in occurrence of cardiovascular diseases. Dr. Vladimir Jakovljevic is highly dedicated to education of students of medicine, pharmacy, dentistry and postdoctoral students, to whom unselfishly transfer knowledge from the areas of his expertise, using interdisciplinary approach, thus providing strong intellectual basis for future medical doctors, pharmacists, dentists and young investigators. Since 2014

Dr. Vladimir Jakovljevic is a full professor in the field of physiology at the University of Kragujevac.He is president of the Serbian Physiological Society from 2014. Dr. Jakovljevic was directly involved in organization of several eminent scientific meetings, such as 2nd European Section Meeting of the International Academy of Cardiovascular Sciences held in Belgrade in 2015, under the auspices of the International Academy of Cardiovascular Sciences. All the efforts that Dr. Jakovljevic invests in the organization of scientific meetings and spreading of scientific thought, are strongly supported by the Dr. Naranjan Dhalla, men with outstanding energy and passion dedicated to scientific research in the field of Cardiovascular System. Dr. Jakovljevic was awarded by Distinguished Leadership Award in Cardiovascular Sciences in 2015 by International Academy of Cardiovascular Sciences. He was Editor in Chief of the Serbian Journal of Experimental and Clinical Research published by the Faculty of Medical Sciences University of Kragujevac for 10 years. From September 2022, Prof. Jakovljevic is President, European Section, International Academy of Cardiovascular Sciences and from July 2023 President International Society for Pathophysiology.

Professor Jakovljevic has 260 publications, 4.430 citations, and his Hirsch index, according to WoS citation databases is 29. In the 2018. Dr. Vladimir Jakovljevic was elected as the new Dean of the Faculty of Medical Science for a mandate of 3 years. The Council of the Faculty of Medical Sciences unanimously elected Professor Jakovljevic, bearing in mind his exceptional successes as previous Vice-dean for Pharmacy Department. As a new Dean Professor Jakovljevic established cooperation with several universities from all over the world, such as Karolinska Institute (Stockholm, Sweden), The First Moscow State Medical University I.M. Sechenov (Moscow, Russian Federation), Medical Faculty University of Montenegro (Podgorica, Montenegro), and Medical Faculty University of Banja Luka (Banja Luka, Bosnia and Herzegovina). Faculty of Medical Sciences under the leadership of professor Jakovljevic and his team will continue to conquer new scientific and educational heights, always striving towards the higher.He is re-elected in March , 2021 for next 3 years.

From July 10th, 2024 to April 10th, 2025 Prof. Jakovljevic was special advisor to the Minister of education, Republic of Serbia for high education.

Dr. Jagat Narula, Houston, USA

Dr. Jagat Narula

Dr. Jagat Narula, MD, PhD, MACC, is the Executive Vice President and Chief Academic Officer at the University of Texas Health Sciences Center, Houston, where he works with 7 school deans including Medicine, Dentistry, Nursing, Biomedical Sciences, Biomedical Informatics, Behavioral Sciences, and Public Health. He is K. Lance Gould Distinguished University Chair of Coronary Pathophysiology at the McGovern Medical School, Houston He is the President of the World Heart Federation. The following is a synopsis of his achievements:

o **RESEARCH CONTRIBUTIONS:** equally to basic science, clinical investigations and population health, with more than 1,200 peer reviewed publications including the best of clinical medicine (NEJM, Lancet, Circulation, European Heart & Journal of American College) and basic science (Nature, Science, PNAS, Cell) journals, more than 100 research presentations at the cardiovascular scientific meetings, and more than 500 grand rounds, honored or invited lectures. Research funded, in part, by the grants from National Institutes of Health. Notable research contributions are summarized below.

o **APOPTOSIS IN HEART FAILURE:** First to demonstrate the presence of phenomenon of heart muscle cell apoptosis in human heart, initially in heart failure as the basis of inexorable decline in left ventricular function (NEJM 1996). Until then it was tacitly believed that the cells not endowed with regenerative ability such as cardiomyocytes were not empowered to kill themselves. In subsequent clarification of unique phenomenon of (up to) complete loss of contractile proteins as a part of apoptosis (PNAS 2001) wherein the nucleus escaped fragmentation (*apoptosis interruptus*) due to upregulation of novel inhibitors of apoptotic process rendering heart failure to be a reversible process (PNAS 1999) and proposed the relevance of treatment with neurohumoral antagonists. Subsequently develop targeted clinical imaging with radiolabeled Annexin A5 for noninvasive assessment of apoptosis in the living (Nature Medicine 2001). Targeted imaging in the heart failure patients established that myocardium strived to fight the apoptotic factors induced by various insults by producing anti-apoptotic factors (Ann Thor Surg 2005) and the recovery was dependent on the balance of the pro- and anti-apoptotic cascades (Nature Cardiovasc Med 2009); the balance could be determined by Annexin imaging (JNM 2007). Further refined and simplified apoptosis imaging with a tracer of superior imaging characteristics (Tc-99m-labeled Duramycin) (JACC Imaging 2018, 2020), which is proposed to be employed for clinical imaging. Also demonstrated relevance of the process of apoptosis in cardiac allograft rejection, ischemic myocardial injury and high-risk atherosclerotic plaques.

o **CHARACTERIZATION OF HIGH-RISK ATHEROSCLEROTIC PLAQUES:** Working closely with cardiovascular pathologists, proposed histological characteristics and pathogenesis of atherosclerotic lesions in coronary, peripheral and carotid arteries (NEJM 2003, AJP 2000, JACC 2013, Nature Rev Cardiol 2014, JACC 2018). The proposed classification in Hurst's the Heart (2021) offers entirely new insights into the evolution of the atherosclerotic process. Also, credited with founding studies for phenotypic characterization of atherosclerotic lesions with invasive (intra coronary OCT, IVUS, NIRS imaging) and noninvasive (CT angiography, magnetic resonance and molecular imaging) assessment of plaques vulnerable to rupture and at high risk of developing acute coronary events including heart attacks and sudden death. The most important contribution has been the first demonstration of plaque morphology on CT angiography (JACC 2007). Through series of large subsequent clinical longitudinal studies, CT angiography-verified plaque characterization (JACC 2009, 2015; JACC Imaging 2018, 2020, 2021, JAMA Cardiol 2018) is becoming a dayto-day reporting requirement for CT angiography (JCCT 2020, 2021). The latest report of dual-emission CT imaging (manuscripts in press) are promising to identify the basis of plaque inflammation in non-contrast ECG-gated images, which could bring paradigm shift in coronary disease management. The paired intra-coronary series of studies for plaque modification with extensive transcriptomics with lipid lowering agents provide unique phenotype-to-genotype experiments providing pathogenetic insights and development of predctive biomarkers. The proposal of the preferred role of contribution of thrombotic component in critical limb ischemia (moreso than the atherosclerotic pathology) is likely to change the way we treat lower

extremity atherosclerotic disease (JACC 2018). The latest manuscript on the concomitant venous occlusion and grant for proposed lymphatic occlusion are providing new insights into the widely prevalent but ill-understood debilitating disease leading to gangrene and amputations. Contribution to newer classification of carotid atherosclerosis is also under preparation.

o **CARDIOVASCULAR MOLECULAR IMAGING:** Have contributed immensely to the foundation of molecular imaging in cardiovascular medicine, from beginning of post-doctoral career at Massachusetts General Hospital and pioneered the field of subcellular imaging for myocardial necrosis (NEJM 1993) and apoptosis (Nature Medicine 2001) and defined the clinical relevance of targeted imaging. Subsequently, followed up on initial contributions by developing imaging of myocardial interstitial fibrosis (JACC 2008, JACC Imaging 2009); studies were initially undertaken in animal models and appropriately translated to clinical investigation. The laboratory later defined numerous scintigraphy targets for the molecular assessment of high-risk atherosclerotic plaques (publications from Circulation 1995 to JACC 2020, Nature Medicine 2013). The recent proposal of NaF imaging for erectile dysfunction (JACC 2019) from the laboratory is now going to be prospectively tested.

o **GLOBAL HEALTH:** Jagat Narula is heavily invested in investigation at population level and education of masses with the focus on cardiovascular disease prevention and cardiovascular health promotion. Numerous studies are being conducted in various countries including India, Netherlands and UK (Glob Heart 2011, 2013, Ann Glob Health 2019). Novel proposals have been developed through unique studies of heart disease in mummies (Lancet 2013) and ancient populations (Lancet 2017), and now the focus is on neonates and pregnant mothers (EHJ 2021). The recent leadership in international efforts as the President of the World Heart Federation including CARDIO4Cities and City Heartbeat Index are groundbreaking efforts, including the implementation protocols in poor zip codes of Texas in comparison with Zanzibar. Also working on the use of geographically, contextually and culturally relevant studies for delivery of health awareness (HAPPY, ie. Heart Attack Prevention Program for You). RHEUMATIC FEVER: Rheumatic Heart Disease (RHD) and Rheumatic Fever (RF) continue to be important scourge in low- and middle-income countries (LMIC). The PhD thesis topic was dedicated to developing novel diagnostic tools for detection of RF especially with pre-existing RHD. The novel diagnostic proposals (Circulation 1999) included endomyocardial biopsy (Circulation 1993), echocardiography (Circulation 1996) and molecular imaging (Am J Cardiol 1999). Also, leading major initiatives through World Heart Federation including biennial World Congress on RF/RHD in Abu Dhabi. The RF book authored by JN is the only available resource for LMICs.

o **EDUCATION & RESEARCH:** Exploiting imaging technology for medical education including hand-held ultrasound for teaching anatomy/physiology and bedside physical examination (JAMA Cardiology 2018) and CT/MR for anatomy instruction (JACC 2015). Also working on international collaboration for hand-held ultrasound training of midwives in sub-Saharan Africa. Recently started to include entertainment media such as television serials (Lancet 2020) and social influencing (JAMA Open 2020, eClin Med 2020) for education of masses. At least 3 novels are in process of being printed for education of patients as also for cardiovascular health education of school-going children.

o **EDITORIAL RESPONSIBILITIES**: One of the most successful Editors in the field of cardiovascular medicine including cardiovascular imaging, heart failure and global health journals. Editor-in-chief (Founding) of the JACC (Journal of the American College of Cardiology)-Cardiovascular Imaging (official publication of the American College of Cardiology), 2007-2017. Editor-in-Chief (Founding) of 'Global Heart' (official publication of World Heart Federation), 2011-2016. Executive Editor, JACC 2014-2022. Executive Editor, Annals of Global Health (Consortium of Universities of Global Health), 2015-contd. Editor (Founding) of the Heart Failure Clinics of North America, 2004-2007. Editor of the most popular cardiology textbook- Hurst's the Heart (14 & 15th Editions) with Valentin Fuster MD.

o **HONORS & AWARDS:** A selected few awards are listed below. Khanderia Memorial Oration for Global Health & Imaging, American Society of Echocardiography 2025 James T. Willerson Memorial Oration, International Academy of Cardiovascular Sciences, 2025 Julius Gardin Lecture, American Society of Echocardiography 2024 James T. Willerson Memorial Award, Vunerable Plaque Group 2023 Master of the Society of Cardiovascular Computed Tomography, 2021 Henry Wagner Oration, Society of Nuclear Medicine & Molecular Imaging, 2020 International Service Award, American College of Cardiology 2020 Distinguished Fellow Award, American College of Cardiology 2018 Maseri-Florio International Lecture, American College of Cardiology 2016 Agatston Award of the Society of Cardiovascular Computed Tomography, 2016 Distinguished Scientist Award, American College of Cardiology 2015 Master of the American Society of Nuclear Cardiology 2014 Paul Wood Award, National Heart, Lung Institute, UK 2014 Mario Verani Oration of the American Society of Nuclear Cardiology, 2014 Howard Morgan Award for Distinguished Achievements in Cardiovascular Research, International Academy of Cardiovascular Sciences, 2014 Harold

Buchwald Distinguished Oration for Promoting Centers of Excellence and Young Investigators, International Academy of Cardiovascular Sciences, 2014 Anand & Saroj Aggarwal Endowed Lectureship for South Asian Health, 2014 Master of the American College of Cardiology 2013 Gifted Educator Award, American College of Cardiology, 2012 Distinguished Scientist Award, American Heart Association-Orange County, 2011 Mayo Clinic James Seward & Jamil Tajik Award for Excellence in Cardiovascular Imaging, 2010 Einthoven Medal for Excellence in Cardiovascular Imaging, the Netherlands, 2009 Honor of the City of Maastricht, the Netherlands by the Mayor of the City, for contributions to Heart Health of the City, 2008 Best Young Investigator Awards on numerous occasions for research contributions to the field of cardiovascular imaging >35 young investigator mentees from my laboratory have received National & International Young Investigator Awards o Was invited in 2012 to the American College of Cardiology annual meeting, as 1 of the 5 Innovators in Cardiovascular Medicine, during the concluding session; the annual meeting was inaugurated by 5 legends in Cardiology. Was featured as an honored guest for a 16-page interview in the American Journal of Cardiology by the editor. [Roberts WC. A conversation with the editor. Am J Cardiol. 2014;113(12):2070-85. PMID: 24878131]

o **MENTORSHIP:** In leadership roles in cardiology departments and through extensive collaborations with numerous countries for decades, he has trained hundreds of clinical and research fellows and continues to nurture them. His research laboratory fellows come from all over the world, mostly from Japan and the Netherlands, for their docent qualification- PhDs or post-doctoral fellowships. It is rather unimaginable to witness the way mentees bond with him. He would go to his molecular imaging laboratory in after hours and be with fellows until midnight or beyond, helping review their experimental results and analyze data. Fellows routinely go to his house at 4AM on Saturday mornings to write their papers, grants, abstracts or finalize the slides for presentations; these meetings would usually last from 4AM to 1PM. At least 30 of his mentees have received young investigator awards in various scientific forums across the world. This is an unparalleled accomplishment for any cardiovascular medicine laboratory or investigator and speaks of his dedication to the mentees. His Japanese mentees have formed a small society in his honor and hold an annual meeting to discuss their scientific output and proposals, especially when he visits Japan every year; this meeting is named as FAN-JAM (Fellows Associated with Narula-lab. from Japan, Annual Meeting). The students who are not able to present data or proposal feel guilty for not having lived up to his expectations. He often says that the love he receives from his students is the ultimate fulfilment he yearns for.

Dr. Ali J. Marian, Houston, USA



Dr. Ali J. Marian

Dr. Ali J. (AJ) Marian is a physician-scientist with a clinical and research focus on cardiovascular genetics, primarily hereditary cardiomyopathies. Dr. Marian is a Professor of Molecular Medicine (Genetics), Professor of Medicine (Cardiology), and Director of the Center for Cardiovascular Genetic Research at the Brown Foundation Institute of Molecular Medicine at the University of Texas Health Science Center, Houston, TX. Dr. Marian also holds the James T. Willerson Distinguished Chair in Cardiovascular Research at the same University.

Dr. Marian obtained his M.D. degree from Tehran University in Iran in 1981. He completed an Internal Medicine residency at John H. Stroger, Jr. Hospital of Cook County in Chicago, IL, and a Cardiology fellowship at Baylor College of Medicine, Houston, TX. Upon completion of clinical training, he joined The American Heart Association-Bugher Foundation research fellowship program in human molecular genetics, which he completed at Baylor College of Medicine. Dr. Marian joined the faculty in the Section of Cardiology at Baylor College of Medicine in 1992 and rose to the rank of academia to full Professor with tenure in 2006 when he was recruited by Dr. James T. Willerson and Dr. Thomas C. Caskey to the Brown Foundation Institute of Molecular Medicine at the University of Texas Health Science Center, Houston to lead the Center for Cardiovascular Genetic Research.

Dr. Marian's clinical and research programs are focused on hereditary cardiomyopathies. He and his colleagues aim to delineate the molecular genetic basis and pathogenesis of hypertrophic, dilated, and arrhythmogenic

cardiomyopathies. The group has identified several causal and modifier genes and mutations for cardiomyopathies and characterized several pathogenic pathways, including the Hippo, canonical WNT, FOXO, and BET proteins in hereditary cardiomyopathies. More recently, he and his group have focused on delineating the role of DNA damage, including DNA double-stranded breaks and activation of the DNA damage response pathways in the pathogenesis of hereditary cardiomyopathies.

Dr. Marian is a Deputy Editor for Cardiovascular Research. He is a former Deputy Editor for Circulation Research, Associate Editor for Circulation, European Journal of Clinical Investigation, Section Editor of Genetics for Current Opinion in Cardiology, and the Editor-in-Chief and Founding Editor of The Journal of Cardiovascular Aging.

Dr. Marian has published over 200 original research articles and has received several recognitions and awards, including the Established Investigator Award, American Heart Association, Clinician-Scientist Award in Translation Research, Burroughs Wellcome Fund, Best Editor Award from Circulation Research, and Distinguished Scientist Award from Baylor College of Medicine-Luke's Medical Center, and the Lifetime Achievement Award from International Academy of Cardiovascular Sciences.

Dr. Petr Ostadal, Prague, Czech Republic

Dr. Petr Ostadal

Professor Petr Ostadal received his medical degree (MD) in 1996 from the Second Faculty of Medicine at Charles University in Prague, Czech Republic. He began his professional career at the Department of Internal Medicine of the same faculty and at Motol University Hospital, where he worked from 1996 to 1999. That same year, he passed the Internal Medicine Board examination in Prague.

From 1999 to 2006, he worked at the Coronary Care Unit within the Departments of Medicine and Cardiology at the Second Faculty of Medicine and Motol University Hospital. In 2001, he undertook a PhD research fellowship at the Institute of Cardiovascular Sciences, St. Boniface Research Centre in Winnipeg, Canada. He was certified by the Cardiology Board in 2003 and earned his PhD degree in 2004 from the Second Faculty of Medicine, Charles University. Between 2006 and 2008, Professor Ostadal served as Head of Coronary Care Unit C at the Department of Cardiology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady. In 2006, he was appointed Associate Professor of Medicine at Charles University, and in 2007, he became a Fellow of the European Society of Cardiology (FESC). From 2008 to 2023, he was Head of the Acute Cardiac Care Unit at the Department of Cardiology, Cardiovascular Center at Na Homolce Hospital in Prague. At the same time, he continued his affiliation with the Department of Internal Medicine at the Second Faculty of Medicine and Motol University Hospital. From 2010 to 2023, he also served as Deputy Head of the Department of Cardiology at Na Homolce Hospital.

In 2020, he was appointed Professor of Medicine at the Second Faculty of Medicine, Charles University. Since 2023, he has been serving as Head of the Department of Cardiology at the same institution and hospital. In that year, he was also elected Fellow of the International Academy of Cardiovascular Sciences (FIACS).

Professor Ostadal currently serves as President of the Czech Society of Cardiology (2023–2027). He is a Board Member and past Chairman of the Czech Acute Cardiac Care Association, and he also serves on the board of the Czech Heart Failure Association. He is a Council Member of the European Section of the International Academy of Cardiovascular Sciences. Professor Ostadal has published extensively in the field of acute and intensive cardiovascular care, especially hemodynamics, cardiogenic shock, cardiac arrest, mechanical circulatory support, acute coronary syndromes, and lipid-lowering therapy. His scholarly output includes six books and twenty-two book chapters. He is the author or co-author of 192 publications indexed in the Web of Science. His work has been cited 7,691 times (excluding self-citations), and his H-index, according to the Web of Science, is 26.

Dr. Ravichandran Ramasamy, New York, USA

Dr. Ravichandran Ramasamy

Dr. Ravi Ramasamy is an internationally recognized scientist for his research on the metabolic basis of myocardial ischemia-reperfusion injury and heart failure. Specifically, his pioneering research demonstrated the role of aldose reductase and RAGE receptor in mediating injury after myocardial infarction in diabetics and non-diabetics.

Dr. Ramasamy received his PhD (Chemistry) from Loyola University Chicago in 1989. He completed his post-doctoral fellowship at University of Texas at Dallas & University of Texas Southwestern Medical Center, Dallas. He joined University of California Davis as an instructor and rose to the rank of Assistant Professor in 1992. He was recruited by Columbia University Medical Center in 1997 to embark on myocardial metabolism and diabetic complications research. He rose to the ranks of Associate Professor and Director of Cardiovascular Complications Laboratory. Subsequent, he was recruited by New York University Langone Medical Center in 2010 to co-direct the Diabetes Research program, where he is currently a Tenured Full Professor of Biochemistry, Molecular Pharmacology & Medicine.

Dr. Ravi Ramasamy is known for innovative studies in the fields of myocardial ischemia-reperfusion injury, diabetic cardiovascular complications, and, more recently, cardiovascular dysfunction in aging. His recent discovery of key molecular mediators of inter-organelle contact has led to establishing inter-organelle communication as a therapeutic target for protection against cardiac ischemia and diabetic vascular complications. Dr. Ramasamy's research utilizes the tools of basic science to address issues relevant to important clinical problems in cardiovascular disease and diabetic complications. His current research is focused on novel means of dissecting interaction between inter-organelle, metabolic and signaling pathways in cardiac ischemic injury, inflammation, and aging.

Dr. Ravi Ramasamy has been the recipient of Harold and Golden Lamport Award for Excellence in Clinical Research at Columbia University, an Established Investigator award from American Heart Association, and a career development award from American Diabetes Association. He was the JNICT Program, Praxis XXI Visiting Scientist, at the University of Coimbra, Portugal. He was elected Fellow of the International Academy of Cardiovascular Sciences in 2021. His research is funded by the National Institutes of Health and other research foundations. His publications include over 130 peer-reviewed papers and over 75 review/book chapters/editorial commentaries.

Dr. Ravi Ramasamy holds patent on applications of MR contrast agents and use of aldose reductase inhibitors and RAGE receptor blockers in treating ischemic heart disease and diabetic complications. Licensing of these intellectual properties has led to startup companies and ongoing clinical trials. Importantly, his discovery on aldose reductase as a key mediator of ischemic injury and heart failure has led to the Phase3 ARISE-HF clinical trials on aldose reductase inhibitors for diabetic heart disease.

Dr. Ravi Ramasamy serves on grant review panels for National Institutes of Health (US), American Heart Association, American Diabetes Association, Juvenile Diabetes Research Foundation, and American Federation for Aging Research. He is currently the Associate Editor, of the journal "Atherosclerosis Thrombosis and Vascular Biology (ATVB).

Dr. Ravi Ramasamy has dedicated his life and career to basic research and teaching. Driven by the complexities of mechanisms that underlie cardiovascular pathologies, the goal of his laboratory is to uncover key pathways that mediate ischemic injury, metabolic imbalances, heart failure and diabetic cardiomyopathy. It is his hope and expectation that therapeutic targets and interventions discovered from these studies will be employed in the near future to treat patients with evolving myocardial infarction, diabetic cardiomyopathy and ischemic heart failure.

Dr. Jianyi "Jay" Zhang, Birmingham, USA

Dr. Jianyi "Jay" Zhang

Dr. Jianyi "Jay" Zhang, M.D., Ph.D., is an international leader in myocardial bioenergetics, and cells/cell-products for cardiac repair. He is a tenured Professor of Medicine and of Engineering; T. Michael and Gillian Goodrich Endowed Chair of Engineering Leadership; and the Chair of the Department of Biomedical Engineering (BME).

He came to UAB in October 2015 after he was chosen in a national search to lead the UAB BME department from the University of Minnesota Medical School, where he was the Engdahl Family Foundation Chair in Cardiovascular Regenerative Therapies, in addition to being a tenured professor of medicine, of biomedical engineering, of electrical engineering, and computer engineering. Zhang earned his M.D. from Shanghai Medical University in 1983 and his Ph.D. in biomedical engineering from the University of Minnesota in 1992. Since his arrival at UAB, the Department of Biomedical Engineering rose to the rank of top 10th in the nation in NIH funding (Blue Ridge Institute) in the past 7 years consecutively under Zhang's leadership. Dr. Zhang has mentored 21 PhD students earned their PhD degree from University of Minnesota or UAB. Dr. Zhang's research interests include iPS technology, heart failure, cell-products for cardiac repair. He is currently the PI of NIH multiple R01 grants, one NIH U01 grant, and one PPG that through 2027.

The Zhang lab has published >200 papers in high impact journals including Circulation, Circulation Research, Cell Stem Cell, Science Translational Medicine research; he has trained more than 90 trainees, and led 21 students earning their Ph.D. He is Charter Reviewer on NIH study section (HLBP, through 2026); editorial board member for Circulation, Circulation Research, and others.

Dr. Maria I. Kontaridis, Utica, USA

Dr. Maria I. Kontaridis

Dr. Maria Irene Kontaridis is the Executive Director, Gordon K. Moe Professor and Chair of Biomedical Research and Translational Medicine, and the Director of Research at the Masonic Medical Research Institute (MMRI) in Utica, NY. She also holds a part-time faculty appointment as an Associate Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center (BIDMC), in the Department of Medicine/Division of Cardiology in Boston, MA, USA.

Dr. Kontaridis received her undergraduate degrees (B.A. and a B.S.) from the University of Florida in Classics and Chemistry and subsequently obtained her master's degrees in pharmacology and biomedical and Biological Sciences from Yale University in 1999 and 2001, respectively. In 2002, she was awarded a Ph.D. from Yale University for work with Dr. Anton Bennett on the role of protein tyrosine phosphatases, especially SHP2, in cell growth and skeletal muscle differentiation. Dr. Kontaridis' interest in continuing to work on SHP2 phosphatase led her to accept a postdoctoral position with Dr. Benjamin Neel, at BIDMC in 2003.

Her work as a postdoctoral fellow garnered extramural support from the American Heart Association and the NIH Pathway to Independence Award (K99/R00). In 2007, Dr. Kontaridis was promoted to Instructor, and in 2008, was recruited to the Department of Medicine, Division of Cardiology at BIDMC as an Assistant Professor of Medicine at Harvard Medical School. In 2015, she was named Director of Basic Cardiovascular Research and in 2016 was promoted to Associate Professor of Medicine at

Harvard Medical School. In 2018, Dr. Kontaridis moved to the MMRI in Utica, NY to become the Director of Research, and in 2020, she was promoted to Executive Director.

Dr. Kontaridis' independent research program focuses on the fundamental mechanisms underlying congenital heart disease and end-stage heart failure, as well as the processes that lead to abnormal development, aberrant signaling and disease onset of lupus, gastrointestinal disease, autism, and cancer. Her lab utilizes a myriad of tools and techniques, including iPSCs, genetic mouse model systems, and molecular biology techniques. Her work has been awarded grants from the Milton Foundation, the Children's Cardiomyopathy Foundation, the Saving Tiny Hearts Foundation, the Harvard Stem Cell Institute, the Alliance of Lupus Research, Lupus and Allied Diseases, Inc, the American Heart Association (AHA), Department of Defense (DOD), and the National Institutes of Health (NHLBI-R01s and NCATS-TRND), and has garnered support from industry and pharmaceutical companies (Onconova, Novartis, GSK, Arqule).

Dr. Kontaridis is also actively involved in the medical and research communities and has established herself in several significant leadership roles. In Boston, she served as co-chair for the Joint Committee on the Status of Women at Harvard Medical School and as Chair of the Research Safety Committee at BIDMC and as a member of the Harvard Medical School Biomedical and Biological Sciences Faculty Program. Locally, she serves on the Boards of the Mohawk Valley American Heart Association Chapter, the Mohawk Valley Economic Development Growth Enterprises and the Kelberman Foundation (Autism).

Nationally, Dr. Kontaridis is an appointed Fellow of the American Heart Association (AHA) and served as Chair of the Early Career Committee for the BCVS, Chair of the AHA Early Career Councils on the Council of Operations Committee, and as member of the National AHA Manuscript Committee. She is currently the Chair of the Basic Cardiovascular Sciences Council (BCVS). Dr. Kontaridis is also an elected Council member for the International Society for Heart Research-North American Section (ISHR-NAS). She has also co-chaired and organized the Weinstein Conference for Developmental Cardiology in 2015, the AHA BCVS Summer Conference in 2016, and is the co- chair for the Olympiad in Cardiovascular Medicine Symposium in Greece, which occurs every 4 years.

IACS Honors and Awards at the 11th IACS-European Section Meeting in Prague, Czech Republic

Dr. Grant Pierce, President of the International Academy of Cardiovascular Sciences (World) is most pleased to announce that the following IACS honours and awards will be bestowed upon individuals at the 11th Meeting of the IACS-European Section in Prague, Czech Republic, during November 2-4, 2025.

1. **Bohuslav Ostadal Award for Excellence in Cardiovascular Sciences**- *Dr. Joseph Hill*
2. **Karl Werdan Award for Excellence in Cardiovascular Sciences**- *Dr. Buddha Dawn*
3. **Lorrie Kirshenbaum Award for Excellence in Cardiovascular Science**- *Dr. Marketa Hlavackova*
4. **Andras Varro Award for Excellence in Cardiovascular Sciences**- *Dr. Milos Stojiljkovic*
5. **Vladimir Jakovljevic Award for Excellence in Cardiovascular Sciences**- *Dr. Ricardo Gelpi*
6. **Jan Slezak Award in Cardiovascular Sciences**- *Dr. Gerd Heusch*
7. **Vladimir Jakovljevic Award for Excellence in Cardiovascular Sciences**- *Dr. Rodolphe Fischmeister*
8. **Lorrie Kirshenbaum Award for Excellence in Cardiovascular Science**- *Dr. Dragan Djuric*
9. **Bohuslav Ostadal Award for Excellence in Cardiovascular Sciences** - *Dr. Rhian M. Touyz*
10. **Andras Varro Award for Excellence in Cardiovascular Sciences** - *Dr. Roberto Bolli*
11. **Naranjan Dhalla Honorary Lecture Medal**- *Dr. Suresh C. Tyagi*

Dr. Joseph Hill, Dallas, USA



Dr. Joseph Hill

Dr. Joseph Hill is a cardiologist-scientist whose research focuses on molecular mechanisms of remodeling in the disease-stressed myocardium. He graduated with an MD, PhD from Duke University. Next, he pursued postdoctoral scientific training at the Institut Pasteur in Paris, followed by clinical training in Internal Medicine and Cardiology at the Brigham and Women's Hospital, Harvard Medical School. Dr. Hill served on the faculty of the University of Iowa for 5 years before moving in 2002 to the University of Texas Southwestern Medical Center to assume the role of Chief of Cardiology and Director of the Harry S. Moss Heart Center. Dr. Hill's research group strives to decipher mechanisms of structural, functional, metabolic, and electrical remodeling in heart disease with an eye toward therapeutic intervention.

Dr. Hill serves on numerous committees, boards, and study sections, and he lectures widely. In addition, he serves on several editorial boards, including *Circulation Research: Senior Consulting Editor*, *American Journal of Physiology, Heart and Circulatory Physiology, and American Journal of Cardiology*. He is Editor-in-Chief of the textbook *Muscle: Fundamental Biology and Mechanisms of Disease*. He has received numerous recognitions and awards, including election to the Association of American Professors; he recently served as President of the Association of University Cardiologists and chair of the Academic Council of the American College of Cardiology. He received the 2018 Research Achievement Award from the International Society for Heart Research, the 2020 Lucian Award from McGill University, delivered the William Harvey Lecture this year at the European Society of Cardiology, and received the 2023 Medal of Merit from the International Academy of Cardiovascular Sciences. Presently, he serves as Editor-in-Chief of *Circulation*, the highest-ranking cardiovascular journal. Dr. Hill maintains an active clinical practice focusing on general cardiology, heart failure, and hypertension.

Dr. Buddha Dawn, Las Vegas, USA



Dr. Buddha Dawn

Dr. Buddhadeb (Buddha) Dawn is the inaugural Chairman of the Department of Internal Medicine and Chief of the Division of Cardiovascular Medicine at the Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas (UNLV).

Dr. Dawn received his medical degree from the Medical College, Calcutta, and underwent advanced training in Internal Medicine and Cardiology in India. In the USA, he completed residency in Internal Medicine at the University of Missouri-Columbia and fellowship in Cardiology at the University of Louisville, and then became a faculty in the Division of Cardiology at UofL. In 2009, he moved to the University of Kansas Medical Center as the Maureen and Marvin Dunn Professor and Director of the Division of Cardiovascular Diseases, and Vice Chair for Research in the Department of Internal Medicine. At KUMC, Dr. Dawn was also the founding Director of Cardiovascular Research Institute since 2009, and the founding Director of Midwest Stem Cell Therapy Center (MSCTC) since 2013. He joined UNLV in July 2018.

Dr. Dawn's research interests have evolved over the years from cardioprotection and cardiac cytokine signaling to cardiac repair with adult stem cells. His early work identified the involvement of cytokines, including TNF-α and IL-6 in the development of the late phase of ischemic preconditioning. With regard to clinical cell therapy, his group performed the first comprehensive meta-analysis of pooled data from clinical trials of bone marrow cell therapy in patients with ischemic heart disease. More recent work from his laboratory has demonstrated the perils of heart repair with unmodified induced pluripotent stem cells with regard to tumor formation, and highlighted the advantages of using extracellular vesicles. His laboratory has also been working with a specific cell type from the cord blood that has an immune-privileged phenotype. As a translational scientist, it is immensely gratifying to Dr. Dawn that a specific type of mesenchymal stem cell (MSC) from the Wharton's jelly (umbilical cord) produced by MSCTC has shown promise in a phase 1 trial in patients with severe graft-vs-host disease. This particular type of MSC has significant immune-modulating properties, and is currently being considered in other human pathologies. Dr. Dawn has published more than 200 articles and book chapters, and work from his laboratory has been presented on more than 200 occasions at scientific meetings.

He has been a member of numerous grant review panels, and serves on the Editorial Board of multiple journals. He has delivered invited lectures at many academic institutions and scientific meetings in the US and abroad. Dr. Dawn has received many awards and honors and served on a multitude of local and national committees.

Aside from his passion for science, the education of postdoctoral fellows, residents, and medical students has always been a top priority for Dr. Dawn. At UNLV, Dr. Dawn's team works tirelessly to enhance the education and learning experience of more than 115 trainee physicians in the department across diverse disciplines. Several of Dr. Dawn's former trainees have successfully launched their academic careers at academic institutions in the US and abroad. Dr. Dawn firmly believes that selfless mentoring and succession planning should be integral parts of our academic mission and activities.

As a consummate physician-scientist, Dr. Dawn has practiced medicine and cardiology for three decades. Echocardiography is his primary area of expertise, and his clinical interests are focused on atrial fibrillation and clinical cell therapy. At this stage of his career, program building and mentoring remain his top priorities. Dr. Dawn feels very fortunate to have the privilege of taking care of patients, pursuing scientific discoveries in the lab, and educating the next generations of physicians, scientists, and academic leaders.

All Trainees, Graduate Students and Post-Doctoral Fellows are encouraged to attend the meeting and present their work in the poster award competitions.

Dr. Markéta Hlaváčková, Prague, Czech Republic

Dr. Markéta Hlaváčková

Dr. Markéta Hlaváčková, Ph.D. is Head of the Laboratory of Developmental Cardiology at the Institute of Physiology of the Czech Academy of Sciences in Prague. She earned her Ph.D. in Biochemistry in 2012 from the Faculty of Science, Charles University in Prague. Her scientific training includes postdoctoral fellowships at the Institute of Cardiovascular Sciences, St. Boniface Hospital Research (Canada), and at the Center for Metabolic and Vascular Biology, Arizona State University (USA). She has also completed several international research internships at the Free University in Amsterdam (Netherlands).

Dr. Hlaváčková's research lies at the intersection of cardiovascular physiology, molecular biology, and RNA epigenetics (epitranscriptomics). Her early work investigated the long-lasting cardioprotective effects conferred by chronic hypoxia, exercise, and dietary interventions, with a focus on protein kinase C signaling pathways. More recently, her research has centered on epitranscriptomic regulation in cardiac biology, with an emphasis on RNA modifications such as N^6-methyladenosine (m^6A) and N^6,2′-O-dimethyladenosine (m^6Am). Her studies explore the roles of these modifications in ischemia-reperfusion injury, hypoxic tolerance, diabetes progression and early-life programming of cardiac function. Her findings have identified RNA demethylation as a key adaptive mechanism in cardioprotection and metabolic homeostasis.

Dr. Hlaváčková has authored more than 35 peer-reviewed articles and three book chapters. She has presented her work as an invited speaker at leading international conferences, including New Frontiers in Basic Cardiovascular Research, the International Academy of Cardiovascular Sciences and the International Society for Heart Research. Her scientific contributions have been recognized with several awards from international meetings and funding agencies. She has led multiple research projects in collaboration with clinical cardiologists and international experts in the field of RNA modification. She has also actively participated in EU-funded research initiatives, including the CardioRNA COST Action and the Cardioprotection COST Action. In addition to her research, Dr. Hlaváčková is committed to teaching and mentoring. She lectures at Charles University, where she leads graduate-level courses, and has supervised both undergraduate and Ph.D. students, including two who have successfully defended their dissertations. In 2024, she assumed her current leadership role, continuing to investigate how hypoxia and epigenetic regulation shape cardiac health and disease.

Dr. Miloš P. Stojiljković, Banja Luka, Bosnia & Herzegovina and Republic of Srpska

Dr. Miloš P. Stojiljković

Dr. Miloš P. Stojiljković earned his MD degree in 1984 from the Medical Faculty, University of Sarajevo, MSc degree in 1991 and Clinical Pharmacologist specialist degree in 1992, both from the Medical Faculty, University of Belgrade and PhD degree in 1996, from the Military Medical Academy in Belgrade.

Dr. Stojiljković is Full Professor of Pharmacology, Toxicology and Clinical Pharmacology and PhD Programme Director, Faculty of Medicine, University of Banja Luka (since 2017); Visiting Professor, Faculty of Medical Sciences, University of Kragujevac (since 2024); President of the Society of Toxicology of the Republic of Srpska (2025-present); Member of the IACS EU Council (since 2022). He has held the positions of Vice-Dean, Scientific Research and Postgraduate Education, Faculty of Medicine, University of Banja Luka (2018-2024).

Dr. Stojiljković conducted his postdoctoral studies at the Medical University of South Carolina (1999-2000); Executive MBA studies, City College, University of Sheffield (2007-2009). He is Principal investigator in national-funded grants (since 2020). Until 2025 he published 250 bibliographic units with 77 publications indexed in PubMed; 11 chapters in books/monographs; he wrote or edited/co-edited 6 books in a field of physiology, pharmacology and toxicology, including one with Academic Press "Handbook of Toxicology of Chemical Warfare Agents" (2020) and two Springer Nature books entitled "Environmental Factors in the Pathogenesis of Cardiovascular Diseases" (2024) and "Cardiovascular Toxicity: Incidence, Pathogenesis, and Treatment Strategies" (2025), the latter he also co-edited. He has been involved in organisation of many scientific events in Serbia and abroad, including co-chairing of the 7th Meeting of the European Section and 8th Meeting of the North American Section of the International Academy of Cardiovascular Sciences (IACS) in Banja Luka, The Republic of Srpska, Bosnia and Herzegovina (2021).

Dr. Stojiljković has received several awards, most notably the IACS: Distinguished Leadership Award, Vincenzo Panagia Distinguished Lecture Award; Elected Fellow of the International Academy of Cardiovascular Sciences (2022); Associate Member, Society of Toxicology (SOT), USA (2025); Associate Member, Academy of Medical Sciences, Serbian Medical Society (2025); Member, Scientific Society of Serbia (2025).

Dr. Ricardo Gelpi, Buenos Aires, Argentina

Dr. Ricardo Gelpi

Professor Ricardo J Gelpi was born in La Plata, Argentina. He obtained a Bachelor's degree from Normal School No. 3, Almafuerte, graduated as a physician from the Faculty of Medicine of the National University of La Plata (UNLP) in 1975, and as Doctor in Medicine in the year 1981 at the same university. His Doctoral thesis director was Professor Horacio Cingolani, who was also his director for doctoral scholarships for four years working at the Center for Cardiovascular Research (CIC), financed by National Scientific and Technological Research Council (CONICET). After the doctoral scholarships, Professor Gelpi began his scientific research career at CONICET and continued working under Professor Cingolani for approximately five more years. Parallel to his research work, Professor Gelpi started teaching at the Department of Physiology with Biophysics of the UNLP Faculty of Medicine. He initially worked as Instructor and then, after a severe competitive evaluation, as Head of Instructors. He was always exclusively dedicated to research and teaching since his graduation. In 1985, he obtained an external scholarship from CONICET to work for two years at the New England Regional Primate Research Center

(NERPRC), belonging to Harvard University, USA, under the supervision of Professor Steve Vatner. During those two years he worked on a project on left ventricular function and myocardial hypertrophy secondary to pressure overload by aortic stenosis and arterial hypertension. Once the scholarship in Harvard concluded, Professor Gelpi continued working for several more years with Professor Vatner. Those were very productive years which were reflected in seven publications in high-impact journals and one chapter. In addition to their mutual scientific interest, they developed an ongoing friendship that continues to these days. Upon returning to Argentina, he resumed his work at the CIC again under the supervision of Professor Cingolani during approximately four more years. In 1992, he received an offer to work in the Pathology Department of the Faculty of Medicine of the University of Buenos Aires, a position that he accepted. In 2002 he created the Institute of Cardiovascular Physiopathology (INFICA), obtaining the position of director after competitive evaluation.

Also, in 1992 and by the initiative of several well recognized Latin American basic and clinical researchers, such as for example Professors Horacio Cingolani from Argentina, Raul Domenech from Chile, Otoni Moreira Gomes and Paulo Tucci from Brazil, Luis Folle from Uruguay, and others, he became involved with the International Academy of Cardiovascular Science (IACS). This was a very important milestone that allowed him to actively engage not only with the cardiovascular research projects in Latin America but also in the rest of the world. By collaborating with IACS, a period of very intense activity began which allowed him to annually organize the Society's scientific meetings in several different countries of Latin America, mainly Brazil, in collaboration with Professor Otoni Moreira Gomes. In these meetings, a very important issue was that undergraduate, and postgraduate teaching were promoted along with research.

Professor Gelpi was elected as a Fellow of the International Academy of Cardiovascular Sciences (FIACS, 2002). In 2004, Professor Gelpi had the privilege and honor of being appointed the first president of the Latin American section of IACS, and from that designation his participation in science and teaching in Latin America increased, always motivated by IACS. Years later, he has been awarded with Distinguished Leadership Award in Cardiovascular Sciences, International Academy of Cardiovascular Sciences (2014). He also received the Argentine Society of Cardiology Award, the Young investigator Argentine Society of Cardiology Award, and the Argentine Society of Clinical Investigation Award. That intense period of activity in Latin America concurs with his designation as Adjunct Professor, and in two years as Full Professor and Director of the Pathology Department of the University of Buenos Aires Faculty of Medicine. Therefore, his academic position is consolidated for both cardiovascular research and undergraduate and postgraduate teaching.

As a proof of his permanent interest in stimulating scientific research in Argentina, he founded the Basic Research Council of the Argentine Society of Cardiology in 1998, and the Undergraduate Student Association for Scientific Research of the University of Buenos Aires (AECUBA) in 2002.

In 2003 he was elected Vice Dean, and in 2017 Dean of the University of Buenos Aires Faculty of Medicine.
In 2022, having completed his appointment as Dean of the Faculty of Medicine, Professor Gelpi was appointed Rector of the University of Buenos Aires for the period 2022-2027. This university is ranked 70th in the QS rankings, one of the top three in Latin America. This important position allows Professor Gelpi to increase the university's international presence, both in academic and scientific aspects. Of particular importance is that in 2024, Professor Gelpi was appointed President of the Macro Network of Universities, which includes the most prestigious universities in Latin America.

Thus, Professor Gelpi holds the highest responsibility in the governance of the University of Buenos Aires, having access to important academic and scientific decisions not only in Argentina but also internationally.

Despite being heavily involved in the governance of the University of Buenos Aires, Professor Gelpi continued his cardiovascular research work and teaching. In the past few years, he worked in different projects related to heart protection during myocardial ischemia, particularly the role of thioredoxin and remote ischemic preconditioning and postconditioning. Regarding myocardial ischemia, he began Neurocardiology projects and specifically studied the role of vagal stimulation in myocardial protection. His teaching vocation also allowed him to approach diverse humanistic and bioethical topics, introducing himself in the study of different medical oaths. This was reflected in several published articles and doctoral thesis on the subject matter.

Dr. Gerd Heusch, Essen, Germany

Dr. Gerd Heusch

Professor Gerd Heusch studied medicine at the Universities of Düsseldorf and Bonn (MD in 1980). From 1980 to 1985 he was a postdoctoral fellow in the Department of Physiology at the University of Düsseldorf (PhD in 1985). From 1985 to 1986 he was research cardiologist at the University of California, San Diego under Dr. John Ross Jr. He received a Heisenberg scholarship from the German Research Foundation which he used for further work and clinical training in the Departments of Physiology and Cardiology (Prof. Franz Loogen). From 1989 to 2024 he was professor and chair of the Institute for Pathophysiology at the University of Essen. His major research interests are the control of coronary blood flow, myocardial ischemia/reperfusion injury and cardioprotective strategies. He has authored more than 650 original and review articles, his h-index is triple digit.

Heusch has been president of the German Cardiac Society (2007-2009) and of the European Section of the International Society for Heart Research (2002-2005); he has also been governor of the German Chapter of the American College of Cardiology and is currently councillor of the International Academy of Cardiovascular Sciences. He has served as speaker of the medical board of the German Research Foundation and currently serves as president of the Nordrhein-Westphalian Academy of Sciences and Arts. He has been awarded the William Harvey Lecture and Silver Medal of the European Society of Cardiology, the Keith Reimer award of the International Society for Heart Research, the Carl Ludwig award of the German Cardiac Society and the Carl Wiggers award of the American Physiological Society. The Medical Academy of Nishnij Novgorord (2000) and the Semmelweis University Budapest (2023) have awarded him an honour´s doctorate. He is editor of Basic Research in Cardiology since 1992 and serves as editorial board member of other prestigious journals. In 2012 he was awarded the cross of merit and in 2023 the cross of merit 1. class by the president of the Federal Republic of Germany.

Dr. Rodolphe Fischmeister, Orsay, France



Dr. Rodolphe Fischmeister

Dr. Rodolphe Fischmeister is Emeritus Director of Research at INSERM, former head and founder of the LabEx LERMIT and honorary director and founder of the Laboratory of Signalling and Cardiovascular Pathophysiology - Inserm unit 1180. His lab is based at the Faculty of Pharmacy of the University of Paris-Saclay.

After graduating as an electrical engineer from Supélec in 1978, he moved first to theoretical biology for doctoral studies (PhD in 1980) and then to cellular physiology during the 2 1/2 years of postdoctoral studies at Dalhousie University (Halifax, Canada) and Emory University (Atlanta, GA, USA). He returned to France in 1983 and became a researcher at INSERM. He obtained a Doctorat d'Etat ès Sciences in 1987.

His main research interests are directed toward physiological and pathophysiological aspects of neuroendocrine regulation of heart function, cardiac membrane receptors and their signalling cascades, and cellular control of cardiac ion channels. His combined approach to organ physiology, cellular electrophysiology, fluorescent imaging, molecular biology and biochemistry has led him to unveil major paradigms in cardiac pathophysiology now forming the basis of current knowledge. He demonstrated that intracellular

microdomains of cAMP and cGMP signaling govern the various responses of the heart to hormones and neuromediators such as catecholamines, natriuretic peptides and NO. He showed that these domains are controlled by a large family of phosphodiesterases (PDEs), enzymes responsible for the degradation of cAMP and cGMP. He also showed that PDEs are strongly modified during hypertrophy and heart failure (HF), resulting in a loss of signaling compartmentation that favors disease progression. He showed recently that activation of specific PDEs can restore cAMP compartmentation in the failing heart, a proof of concept for a novel therapeutic approach in HF.

Dr. Fischmeister has published over 200 papers; including 180 in peer-reviewed international journals, accumulated >11000 citations (with 35 papers cited >100 times), and his current H-index is 61. He has been invited to 160 scientific meetings and >100 seminars around the world. He has served as external referee for NIH, NSF, MRC, Wellcome Trust, CNR, Telethon, Government of Canada, etc. He has reviewed papers for >20 different journals and is currently on the Editorial board of *Circulation*. He has been President of an INSERM Study Section (2008-2012), vice-Dean of research of the Faculty of Pharmacy of University Paris-Sud (2015-2020) and deputy vice-president of research for life sciences of the University Paris-Saclay (2020-2022). He is an elected member of a number of professional organizations, member of the Academia Europaea, Past-President of the European Section of the ISHR. He has received several prizes and awards (Jeanne-Philippe Beziat Cardiology Prize 2012, Alain Castaigne Prize 2014, Grand prix de Cardiologie Lamonica 2016, Peter Harris Distinguished Scientist award of the International Society for Heart Research 2022, Naranjan Dhalla Honorary Lecture Medal from the International Academy of Cardiovascular Sciences 2024). He has also trained >30 young post-graduate researchers, half of them coming from foreign countries.

Dr. Dragan Djuric, Belgrade, Serbia

Dr. Dragan M. Djuric

Dr. Dragan M. Djuric earned MD degree in 1987, MS degree in 1991, PhD degree in 1993, and Clinical Physiologist degree in 2007, all from the Faculty of Medicine University of Belgrade. He is a Full Professor of Medical Physiology, Faculty of Medicine, University of Belgrade (since 2008); Visiting Professor, Faculty of Medicine, University of Banja Luka (since 2019); President of the Serbian Association for Arteriosclerosis, Thrombosis and Vascular Biology Research (2003-present); Member of the IACS EU Council (since 2014); Executive Council Member of the IACS World Council (since 2018).

Dr. Djuric was previously Head, Laboratory for Atherosclerosis and Vascular Biology, Dedinje Cardiovascular Institute Belgrade (1996-2000); Chair and Director, Institute of Medical Physiology, Faculty of Medicine, University of Belgrade (2006-2012); Founder and Chair, PhD Program in Physiological Sciences (2009-2024); Adjunct Professor, Faculty of Medical Sciences, University of Kragujevac (2018-2021); President of the Executive Committee or Assembly of the Serbian Physiological Society (2003-2021), Co-founder and Secretary General, Yugoslav Society for the Fight against Atherosclerosis (1998-2002); Member of the Task Force Group on Education in Physiology, Federation of Physiological Societies (2007-2008); Member of the International Society of Pathophysiology Council (2006-2014); Member of the Steering Committee, Global Network for Global Fight Against Cardiovascular Diseases, International Academy of Cardiovascular Sciences (2011).

He undertook postdoctoral training in Germany (Max Planck Institute for Physiological and Clinical Research and Kerckhoff Klinik GmbH, Bad Nauheim, 1998, 2001-2002), and USA (Department of Physiology, College of Medicine, University of South Alabama, Mobile, 2000). He is the Principal Investigator in national-funded grants (since 2005); a MC member in COST actions: CA22169 (2023-2027), the COST Innovation Grant IG16225 (2022-2023), CA18216 (2019-2023), CA16225 RS (2017-2021), CM 1203 (2012-2016), and BM1005 (2011-2015).

Up to May 2025 he published 862 bibliographic units with 220 publications indexed in Web of Science (169 publications indexed in PubMed); 16 publications as collaborator/corporate author; 35 chapters in books/monographs; he has written or edited/co-edited 6 books in a field of medical physiology, 8 books/monographs in the field of endothelium, cardiovascular biology, atherosclerosis, nutrition, and environmental factors, including two Springer Nature books as co-editor entitled

"Environmental Factors in the Pathogenesis of Cardiovascular Diseases" (2024) and "Cardiovascular Toxicity: Incidence, Pathogenesis, and Treatment Strategies" (2025), 15 books of abstracts from scientific meetings, and he was guest editor in 13 special/topic issues of prestigious international journals. National Ministry of Education, Science and Technological Development and EU COST funds his research projects and scientific networking. Dr. Djuric has served on the editorial board of several international journals, and in a few grants review panels, and he was many times reviewer in journals, books, and meetings abstracts. He presented invited lectures 85 times in Serbia as well as 54 times abroad (9 invited guest professor lecture by foreign academic institutions, and 3 invited lectures at FEPS congresses). He has been involved in organization of many scientific events in Serbia and abroad. Dr. Djuric has trained >30 medical students in a research work, and directly supervised and guided 20 graduate students to earn MD-MS and MD-PhD degrees.

Dr. Djuric has received several awards and honours including awards by IACS: Naranjan Dhalla Award for Innovative Investigators in Cardiovascular Sciences (2024), Oration Award Prof. Harpal Buttar (2024), Howard Morgan Award for Distinguished Achievements in Cardiovascular Research (2022), James Willerson Award for Excellence in Cardiovascular Sciences (2021), Distinguished Leadership Award in Cardiovascular Sciences (2019), Andras Varro Award for Excellence in Cardiovascular Sciences (2018), Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery (2015), from European, North American, and Indian sections; Serbian Physiological Society Award for Lifetime Achievement in Physiological Sciences (2016); Elected Fellow of the International Academy of Cardiovascular Sciences (FIACS, 2011); Samuel Racz Medal and Honorary Member for the Contribution in Physiology by the Hungarian Physiological Society (2010); Honorary Member, Bulgarian Society for Cell Biology (2009); Honorary Member, Romanian Society for Laboratory Medicine (2008); Medal of the Yugoslav Society of Cardiology (2002), and Belgrade City October Award (1987). Awarded as the best session organizer at the FFC's 26th International Conference (2019, San Diego, USA), Medal for Contribution to the international affirmation (Faculty of Medicine University of Banja Luka, 2021). Member of the Max Planck Alumni Association since 2021. Elected Fellow of the IUPS Academy of Physiology (FIUPS, 2022).

Dr. Rhian M. Touyz, Montreal, Canada

Dr. Rhian M. Touyz

Dr. Touyz, is the Executive Director and Chief Scientific Officer of the Research Institute of the McGill University Health Centre (RI-MUHC). She is the Canada Research Chair in Cardiovascular Medicine and Dr. Phil Gold Chair in Medicine, McGill University, Montreal. She is also the British Heart Foundation (BHF) Emeritus Chair. She served 10 years as the Director of the Institute of Cardiovascular and Medical Sciences and BHF Chair of Cardiovascular Medicine, University of Glasgow, Scotland, U.K. In 2021 she was recruited to Montreal to direct the RI-MUHC.

Dr. Touyz, a clinician-scientist focusing on molecular mechanisms of hypertension, received her BSc (Hons) (1980), MBBCh (1984), MSc Med (1986) and PhD (1992) in South Africa. She completed her post-doctoral fellowship at the Clinical Research Institute of Montreal and was the Canada Research Chair in Hypertension, University of Ottawa (2005-2011).

She is an elected Fellow of the Academy of Medical Sciences, Royal Society of Edinburgh, College of Physicians, Canadian Academy of Health Sciences and Royal Society of Canada. She has received numerous awards, including the Hypertension Research Excellence Award from the American Heart Association, the highest honour in the field.

Dr. Touyz is the editor-in-chief of Hypertension. She contributes to best clinical practice and co-chairs the 2024 European Society of Cardiology hypertension guidelines. She held leadership roles in premier organizations: President, Canadian Hypertension Society; Chair, Hypertension Council (AHA); President, International Society of Hypertension and Chair, European Council of Cardiovascular Research. She is a strong advocate of equal opportunities for all in academia and research. She founded the 'Women in Hypertension Research Program' of the International Society of Hypertension and led the Silver award Athena Swan program at the Institute of

cardiovascular and Medical Sciences, University of Glasgow. She has spearheaded numerous mentoring schemes for early and mid-career researchers.

She has published 672 peer-reviewed papers [h-index:154; citations 166000]. She has an interest in translational research where her discovery science impacts care of patients with hypertension and cardiovascular disease. Her particular areas of interest include: 1) vascular signaling and redox biology; 2) the renin-angiotensin-aldosterone system; 3) adipose biology and cardiometabolic disease; 4) cardiovascular toxicity of anti-cancer drugs, 5) small vessel disease and vascular dementia, 6) pathophysiology and clinical management of human hypertension. She has supervised over 105 graduate and post-graduate trainees and is committed to mentoring young and mid-career researchers.

Dr. Roberto Bolli, Louisville, USA

Dr. Roberto Bolli

Dr. Bolli graduated from the University of Perugia (Italy) in 1976. He completed a research Fellowship at the NHLBI (1978-80) and a clinical Fellowship in Cardiology at Baylor College of Medicine (1981-83). In 1983, he joined the Faculty at Baylor College of Medicine, where he rose to the rank of Professor with tenure. In 1994, he became Chief of the Division of Cardiovascular Medicine at the University of Louisville, a position that he held for 26 years, until 2020. He is also Director of the Institute of Molecular Cardiology, a Distinguished University Scholar, and the Legacy Foundation of Kentuckiana Distinguished Chair in Cardiology. Twice at two different institutions (Baylor and University of Louisville), Dr. Bolli developed a leading research program starting from zero.

Dr. Bolli has received several major prestigious awards including: Physician Scientist Award, American College of Chest Physicians (1987); Pharmacia-Chiron Young Investigator Award (1988); American Society for Clinical Investigation (1991); Association of American Physicians (1999) ;NIH MERIT Award (2001-2010); Basic Research Prize, Am Heart Assoc (AHA) (2001); Research Achievement Award, International Society for Heart Research (ISHR) (2004); Ken Bowman Research Award, Univ. of Manitoba 2004); Louis and Artur Lucian Award, McGill University (2004); Howard Morgan Award, International Academy of Cardiovascular Sciences (IACS) (2005); Foreign Fellow, Academy of Sciences of the Royal Society of Canada; Distinguished Achievement Award of the AHA (2006); Distinguished Scientist Award of the AHA (2008); Award of Meritorious Achievement of the AHA (2010); Walter B. Cannon Award, Am Physiol Society (2011); Carl J. Wiggers Award, Am Physiol Society (2011) ; Rocovich Gold Medal for Excellence in Science, Edward Via College of Osteopathic Medicine (2012); Medal of Merit of the IACS (2013); Research Achievement Award of the AHA (2013); Peter Harris Distinguished Scientist Award of the ISHR (2015); Jay & Jeanie Schottenstein Prize in Cardiovascular Sciences, The Ohio State University (2015); "Perugian in the World" Award, Camera di Commercio of Perugia (2015); Creation of the Roberto Bolli Young Investigator Award Competition by the International Academy of Cardiovascular Sciences (2016); Honorable Maestro Award, KY Chapter of ACC (2018); Lifetime Achievement Award by the Serbia Physiological Society (2019); Gold Medal, Institute of Cardiovascular Sciences, University of Manitoba (2019); D.Sc. *Honoris Causa*, University of Kragujevac (2019); Listed among Best Medicine Scientists on Research.com (Top 1% 2021, top 2% 2023) and D.Sc. *Honoris Causa*, University of Timisoara (2025)

Dr. Bolli has delivered 361 lectures, including Five plenary lectures and two State-of-the-Art Lectures at AHA Sessions; Landmark Lecture at the ISHR World Congress (2001); Keith Reimer Distinguished Lecture of the ISHR (2002); Robert Berne Distinguished Lecture of the Am Physiological Society (2005); Michel Mirowski Lecture (2006); George E. Brown Memorial Lecture of the AHA (2007); James T. Willerson Lecture (2008); Laurence H. Green Memorial Lecture (2010); Distinguished Scientist Lecture of the AHA (2011); Mikamo Lecture, Japanese Circulation Society (2013); Michael J. Sole Lecture (2013); Keynote Lecture at IACS Congress (2019); Jay Mehta Award Lecture at IACS Congress (2021) and Presidential Lecture at IACS Congress (2022).

His NIH activities include membership of the CVB Study Section, NHLBI Program Project Review Committee, and

NHLBI Advisory Council. Dr. Bolli is Chair of: Pathophysiology Review Committee, Council on Basic Cardiovascular Sciences, Distinguished Scientist Selection Committee, and Council Operations Committee; member of numerous committees; member of the Board of Directors of the AHA. He has served the ISHR as Secretary General, Treasurer, and President and the IACS as President. Dr. Bolli's was Associate Editor of the *Journal of Molecular and Cellular Cardiology,* Guest Editor of *Circulation*, and Editor-in-Chief of *Circulation Research* (2009-2019). He is currently Editor-in-Chief of *Molecular and Cellular Biochemistry*,

Dr. Bolli has been PI in many NIH and DoD grants, including a P01 grant, a UM1 grant (CCTRN), a U24 grant (CAESAR), a DoD grant (CATO), and numerous R01 grants. He has published 510 papers, including 314 original articles. Among the original articles, 45 have appeared in *Circulation Research*, 12 in *PNAS*, 7 in *JCI*, and 32 in *Circulation*. Eighty-four of his papers have been cited more than 100 times, 29 more than 200 times, and 57 more than 300 times. Total number of citations: 65,032; Hirsch factor: 135 (Google Scholar, May 20, 2025).

Dr. Bolli's research has focused on the mechanisms responsible for myocardial ischemia/reperfusion injury and on the development of cardioprotective strategies. His earlier work established a fundamental role of reactive oxygen species in the pathogenesis of myocardial "stunning", a concept that is now accepted as a proven hypothesis. Subsequently, he identified the signal transduction pathways and cardioprotective genes responsible for the late phase of myocardial "preconditioning", thereby elucidating the molecular basis of this adaptation of the heart to stress. His discovery that the cardioprotection afforded by preconditioning is mediated by two proteins commonly thought to be detrimental (inducible NO synthase and cyclooxygenase-2) has impelled a reassessment of current paradigms regarding these enzymes and has paved the way for developing novel pharmacologic or genetic therapeutic strategies in patients with coronary artery disease. He is currently investigating the use of cell therapy to repair injured myocardium. He was the first to show that, contrary to commonly-accepted ideas, cardiac c-kit^{+} cells (CPCs) do not engraft in the heart and, therefore, work via paracrine actions – a concept that has changed our understanding of cell therapy. He has spearheaded the concepts that repeated doses of cells are superior to a single dose and that cells are effective when given intravenously. He led a Clinical Center of the NIH-funded network, CCTRN, where he was PI in two clinical trials: CONCERT-HF and SENECA. He currently leads the DoD-funded CATO trial (A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study of Single or Repeated Intravenous Administration of UC-MSCs in Ischemic Cardiomyopathy).

Dr. Suresh C. Tyagi, Louisville, USA

Dr. Suresh C. Tyagi

The strength of my lab includes cardiovascular remodeling. Remodeling by its very nature implies synthesis and degradation of extracellular matrix (ECM). Our lab is one of the original in Cardiac Remodeling (i.e., we discovered MMP/ADAMTS in the heart early in 1992). For example, we demonstrated the cardiac fibrosis and MMP activation coexist because during reconstitute remodeling ECM, collagen and elastin all are degraded by MMPs but because turnover of elastin is 1000x slower than collagen therefore degraded elastin is also replaced by rapidly synthesized collagen by myofibroblasts. The cardiac ECM remodeling, and reactive and reparative fibrosis terms led to the ideas of resident cardiac precursor/regenerative stem cells. It is our belief that endocardial endothelial-myocyte coupling contributes to cardiac synchronous relaxation and contraction cycle. This is primarily based on our research. Though the role of vascular (including coronary) endothelial in underlying smooth muscle contraction relaxation is studied very well, there is not many studies revealing the contribution of endocardial endothelium in myocyte regulation during systole and diastole.

The epigenetic methylation of any DNA/RNA/Protein, promoter or repressor of genes on chromatin and/or histones generates homocysteine, unequivocally. The strength of our laboratory programs relating to folate 1-carbon metabolism (FOCM) and homocystinuria in cardiovascular system is unique in the sense that it is triggered by epigenetic rhythmic methylation/de-methylation control of gene expression or suppression. The epigenetics by its very nature implies modifications of the genes prior to imprinting and off

printing during the development, health, and disease. We are few of the leaders in the field of epigenetic control of cardiovascular development and disease**,** especially by folate-dependent mechanism. The epigenetic regulation of FOCM in DNA/RNA and histone methylation and acetylation by gene writer and erasers are studied in Dr. Tyagi's laboratory. Based on our findings, the role of nutrition (folate) in "*genetics and epigenetics of preventive medicine*" are addressed.

Our laboratory is one of the few laboratories in creating the chronic congestive cardiopulmonary heart failure (CHF) by creating aorta-vena cava fistula (AVF) in C57 wild type mice. There are basically four ways to create experimental CHF. 1) acute myocardial infarction (MI) model which is ligating the coronary by instrumenting and injuring the heart; 2) Although trans-aortic constriction (TAC) mimics the systematic hypertension, TAC is constricting the aorta on the top of the heart and pressing the heart. 3) there are some acquired models of CHF such as by dietary factors, diabetes/salt diets etc., but these are "single-hit to multiple-hits" models. 4) AVF is the one where AVF is created below the kidney ~1cm, where aorta and vena cava share common middle wall. By creating fistula red blood enters vena cava without an injury to the heart. This model mimics the CHF such as during aging where with age preload keeps increasing than the heart can pump out due to the weaken cardiac myocytes. This also involves right ventricle, lung then to left ventricle, creating congestion. The heart by AVF goes transition from compensatory (HFpEF) to de-compensatory (HFrEF) without multiple hits. There are more models of volume overload, such pacing-induced and mitral valve regurgitation. But these are also injurious models. Our lab is one of the original labs in creating AVF.

Naranjan Dhalla Honoured as Highly Ranked Scholar in the World

Dr. Naranjan S. Dhalla

At a recent ranking announcement, ScholarGPS, Los Angeles (USA) has honoured Dr. Naranjan Dhalla as a 2024 Highly Ranked Scholar in all fields and placed him at 0.05% of 30 million scholars all over the world. He was also recognized as highly ranked scholar in Medicine, Cardiac Physiology and Diabetic Cardiomyopathy worldwide. Dr. Dhalla is a Distinguished Professor at the University of Manitoba, Institute of Cardiovascular Sciences at the St. Boniface Hospital Albrechtsen Research Centre. He has published more than 885 full length research papers and edited 68 books in the field of experimental cardiology. He is Honorary Life-President of the International Academy of Cardiovascular Sciences, Past-President of the International Society for Heart Research and Editor-in-Chief Emeritus of an international journal "Molecular and Cellular Biochemistry". He has received 11 Honorary Degrees (MD, DSc) from different academic institutions, as well as 220 Honours and Awards including Order of Canada, Order of Manitoba and Fellowship of the Royal Society of Canada. Dr. Dhalla has been inducted into the Canadian Medical Hall of Fame (London, Ontario) and has his statue placed in the Citizens Hall of Fame in Winnipeg.

St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, Canada

IACS-North American Section Launches Webinar Series

Under the Direction of Drs. Ali J. Marian and Devendra Agrawal, the IACS-North American Section launched a Webinar Series, aimed to foster collaboration and knowledge-sharing among clinicians, researchers, trainees, and students dedicated to cardiovascular science. The inaugural webinar took place June 3, 2025 featured a keynote lecture Dr. Roberto Bolli.

Dr. Bolli is a world-renowned distinguished clinician-scientist, whose pioneering work in cardioprotection and cell therapy for heart failure is unparalleled. His ground-breaking pre-clinical and clinical studies have advanced the applications of cell therapies in the treatment of heart failure. The recording of the webinar will be available on the Academy website: https://iacsworld.com

Update on the 12th meeting of the North American Section of the Academy, Las Vegas, USA, September 18-20, 2025

There will be several scientific sessions in the field of Clinical, Cellular and Molecular Cardiology, which are being organized by the Program Committee chaired by Dr. Buddha Dawn. In addition, the following scientific sessions will be held at the Las Vegas meeting:

- Advances in Cardiovascular Science
- Advances in Cardiovascular Medicine
- Roberto Bolli Young Investigator Awards Competition
- Gary Lopaschuk Graduate Student Award Competition
- Buddha Dawn Award Symposium for Early Career Investigators
- ICS Symposium for Women Heart Health

In addition to the IACS Medal of Merit, there will be the following 8 Awards for Established Investigators at this conference:

- Howard Morgan Award for Established Investigator in Cardiovascular Sciences
- Naranjan Dhalla Award for Innovative Investigators in Cardiovascular Sciences
- James Willerson Award for Excellence in Cardiovascular Medicine
- Grant Pierce Award for Excellence in Cardiovascular Sciences
- Jawahar (Jay) Mehta Award for Clinical Scientist
- Paul Ganguly Distinguished Lecture Award in Cardiovascular Science
- Suresh Tyagi Award for Excellence in Cardiovascular Sciences
- Amarjit Arneja Distinguished Lecture Award in Prevention of Heart Disease

There will be 8 poster awards in the name of:

- Morris Karmazyn Poster Awards – 4
- Margaret Moffatt Poster Awards - 4

For further information please contact: Dr. Buddhadeb Dawn, MD
Professor and Chairman
Department of Internal Medicine
Kirk Kerkorian School of Medicine
University of Las Vegas
1707 W Charleston Blvd STE 270
Las Vegas, NV 89102, USA
Email: buddha.dawn@unlv.edu


31ST SCIENTIFIC FORUM – INTERNATIONAL CONGRESS OF CARDIOVASCULAR SCIENCES
23RD ANNUAL MEETING OF THE SOUTH AMERICAN SECTION OF THE INTERNATIONAL ACADEMY OF CARDIOVASCULAR SCIENCES
OCTOBER 16-18, 2025
PALMAS, TOCANTINS
CUICA - UFT
CENTRO UNIVERSITÁRIO INTEGRADO DE CIÊNCIA, CULTURA E ARTE
CUICA
LOCALIZAÇÃO
Av. NS 15, 109 - 16a - Plano Diretor Norte, Palmas - TO, 77001-090
PROGRAM DIRECTOR
FURTADO, HENRIQUE B. M.D.
UNIVERSIDADE FEDERAL DO TOCANTINS



31ST SCIENTIFIC FORUM – INTERNATIONAL CONGRESS OF CARDIOVASCULAR SCIENCES
23RD ANNUAL MEETING OF THE SOUTH AMERICAN SECTION OF THE INTERNATIONAL ACADEMY OF CARDIOVASCULAR SCIENCES

Organized by:

The meeting is organized under the auspices of the South American Section of the International Academy of Cardiovascular Sciences (IACS-SAS).

The following scientific topics will be covered:

- Acute and Chronic Coronary Syndrome
- Atherosclerosis
- Arrhythmia and Electrophysiology
- Basic Research
- Cardiac Arrest
- Cardiometabolic Disease
- Cardiovascular Imaging
- Cardiovascular Prevention
- Congenital Heart Disease
- Coronary and Structural Heart Intervention
- Heart Failure
- Hypertension
- Myocardial and Pericardial Disease
- Myocardial Ischemia
- Peripheral Vascular and Aortic Disease
- Pulmonary Circulation
- Rehabilitation
- Valvular Heart Disease
- Advances in Cardiovascular Medicine
- Advances in Cardiovascular Sciences
- Device Therapy



31ST SCIENTIFIC FORUM – INTERNATIONAL CONGRESS OF CARDIOVASCULAR SCIENCES
23RD ANNUAL MEETING OF THE SOUTH AMERICAN SECTION OF THE INTERNATIONAL ACADEMY OF CARDIOVASCULAR SCIENCES

There will be several scientific sessions in the field of Clinical, Cellular and Molecular Cardiology, which are being organized by the Program Committee chaired by Dr. Henrique B. Furtado. In addition, the following scientific sessions will be held at the Palmas meeting:

- Advances in Cardiovascular Science
- Advances in Cardiovascular Medicine
- Otoni Gomes Young Investigator Awards Competition
- Ricardo Gelpi Graduate Student Awards Competition
- Norman Alpert Early Career Investigators Awards Competition
- Dennis B. McNamara Heart Health Awards Competition

In addition to the IACS Medal of Merit, there will be the following 8 Awards for Established Investigators at this conference:

- Otoni Gomes Award- One
- Ricardo Gelpi Award- One
- Norman Alpert Award- One
- Dennis B. McNamara Award- One

Poster Awards

- Melchior Lima Poster Awards (two)
- Antoinette Blackman Awards (two)

For further information please contact:

Dr. Henrique B Furtado, MD
Professor and Chairman Cardiology Department
Medical College of the University of Tocantins - Palmas
Av. LO 03, No 111- 103 Sul, Palmas- TO
CEP 77015-036 Brazil
Email: cardiologiahf1@gmail.com

Update on the 11th meeting of the European Section of the Academy, Prague, Czech Republic, November 2-4, 2025

Dear Researchers and Colleagues,

We are pleased to invite you to participate in the ***Czech Cardiovascular Research and Innovation Days 2025*** and the ***11th European Section Meeting of the International Academy of Cardiovascular Sciences*** held in Prague, Czech Republic, on November 2–4, 2025, at the Vienna House by Wyndham Diplomat Prague Hotel.

This international conference is organized by the Czech Society of Cardiology and the European Section of the International Academy of Cardiovascular Sciences. The official language of the event will be English. Our primary objective is to bring together leading scientists, clinical and experimental cardiologists, research fellows, and trainees to participate in this prestigious scientific forum. We believe this conference will serve as a valuable opportunity to discuss the latest advances in clinical and experimental cardiovascular research.

We look forward to welcoming you to Prague!

Petr Ostadal,
President, Czech Society of Cardiology
On behalf of the Organizing and Programme Committees

This scientific meeting will focus on the following scientific topics:

- Acute and Chronic Coronary Syndrome
- Atherosclerosis
- Arrhythmia and Electrophysiology
- Basic Research
- Cardiac Arrest
- Cardiometabolic Disease
- Cardiovascular Imaging
- Cardiovascular Prevention
- Congenital Heart Disease
- Coronary and Structural Heart Intervention
- Device Therapy
- Heart Failure
- Hypertension
- Myocardial and Pericardial Disease
- Myocardial Ischemia
- Peripheral Vascular and Aortic Disease
- Pulmonary Circulation
- Rehabilitation
- Valvular Heart Disease

Registration Fees:

	Early (until 10.06.2025)	**Standard** (until 02.10.2025)	**Late / On-site**
Regular Registration	130 €	160 €	200 €
PhD Student	30 €	60 €	100 €
Accepted Abstract - 1st Author	0 €	0 €	0 €

The Registration fee includes:

- *access to all sessions,*
- *access to the industry exhibition,*
- *program booklet,*
- *all conference meals (coffee breaks and lunches).*

Call for Abstracts:

All participants are invited to submit their abstract for ORAL or POSTER presentations.

Abstract submission deadline: June 30, 2025.
Abstract can be submitted on-line after registering for **ACTIVE** participation.
First author of an accepted abstract will have their registration fees waived.

Young Investigators Award:

The Organizing and Programme Committee invites investigators under the age of 35 to submit their original paper for the **Roberto Bolli Young Investigators Symposium**.

The posters will be displayed primarily in PRINTED form (the poster stand dimensions are w=100 cm, h=200 cm).

ABSTRACTS SUBMISSION GUIDELINES:

Please use the submission form to upload your abstract.

Text

- maximum of 2500 characters (including spaces)
- abstract text structured into Introduction, Methodology, Results and Conclusion

Authors

- name and surname without titles (*e.g. John Doe*)
- list author's affiliation(s) (*e.g. Dept. of Cardiology, Great University*)
- secondary affiliation can be added after saving
- co-authors can be added after saving
- repeating affiliation can be selected from the list
- if submitted by a co-author the presenting author shall be marked with an asterisk (*e.g.* John Doe*)

Accepted abstracts will be published in **Cor et Vasa**, the journal of the Czech Society of Cardiology and Czech Society for Cardiovascular Surgery.

Meeting Venue & Accommodation:

Vienna House by Wyndham Diplomat Prague Evropská 15 | Prague | Czech Republic
A special accommodation price has been arranged for the Conference participants directly at the Conference Venue. To book the accommodation at this price please use the exclusive **CCvRI Days and IACS-ES reservation link**.

The link will remain open until **September 30, 2025**.

Alternative Accommodation Possibilities:

Hotel DAP	*Hotel International*
website (7 min. walk)	website (10 min. public transport+walk)

Awards:

There will be 10 awards for Established Investigators, in addition to the Naranjan Dhalla Honorary Lecture Medal. Roberto Bolli Young Investigator Symposium is also being organized for Cardiovascular Investigators. There will be 6 poster awards in the name of:

1. Attila Ziegelhoffer (2 awards)
2. Keld Kjeldsen (2 awards)
3. Milosav Kostic (2 awards)

Organizing Agency:

GALÉN - SYMPOSION s.r.o.
Březanská 10
100 00 Praha 10
Czech Republic
tel: +420 222 518 535

Jan Krušina
j.krusina@gsymposion.cz

For further information please contact,
Conference Secretariat:

Prof. Petr Ostadal, MD, PhD, FESC, FIACS
President, Czech Society of Cardiology
Head, Department of Cardiology
Second Faculty of Medicine, Charles University
Motol University Hospital
V Uvalu 84, 15000, Prague, Czech Republic
Phone: +420224434901
E-mail: ostadal.petr@gmail.com

Conference website: www.CzCVRIdays.com

The Objectives of the International Academy of Cardiovascular Sciences

Although great strides have been made in improving the death rate from heart disease, heart attacks and related problems are still the number one killer. The Academy believes that a fundamental problem is the lack of transmission of knowledge to the public. Research has found answers but the facts are too slow in moving beyond the labs. The Academy, through world-wide representation, builds connectivity and encourages networking through traditional means of journals, texts and symposia, as well as consensus panels made up of advisory board members and other experts. The Academy continually pursues new information technologies which will result in more rapid and wider availability of the latest discoveries to help save lives.

Specific objectives of the Academy

To promote the scientific basis for the practice of cardiology and cardiovascular surgery by:

1. Organizing cardiovascular teach-ins all over the world for the continued education of practicing physicians, surgeons and experimental cardiologists
2. Establishing cardiovascular forums in all major cities of the world for increasing the interaction of clinical cardiologists as well as surgeons with basic scientists
3. Setting up national offices of the Academy for coordinating its activities in different countries
4. Cooperating with various national agencies in different countries concerned with the education of medical students, graduate students and postdoctoral fellows
5. Collaborating with various national and international organizations dedicated to both clinical and experimental research in the area of cardiovascular sciences

To foster the exchange of information among cardiovascular scientists by:

1. Establishing national and international networks of various centres and institutions for optimal utilization of resources
2. Promoting exchange programs among different countries through respective governmental agencies
3. Holding scientific symposia on focused topics of current interest
4. Developing news bulletins highlighting different programs of cardiovascular centres and institutes all over the world
5. Publishing cardiovascular journals, books and symposia proceedings as well as developing an interactive for promoting cardiovascular education

To increase public awareness with respect to cardiovascular health and disease by:

1. Making the general public aware of cardiovascular risk factors by holding public seminars and lectures
2. Expressing views on cardiovascular issues through national and international media
3. Cooperating with the national government, public and private agencies concerned with improving cardiovascular health and preventing cardiovascular disease

To recognize the achievements of cardiovascular investigators by:

1. Identifying established investigators of high reputation for awarding Fellowships of the Academy (not more than 250 at any given time)
2. Awarding major prizes to distinguished scientists
3. Selecting young talents for awards and travel grants

To raise funds from individuals and corporate sources for various programs of the Academy by:

1. Naming symposia/workshops/seminars in cardiovascular sciences
2. Making corporate members of the Academy
3. Identifying patrons and supporters of the Academy

For further information, please visit:
www.iacsworld.com

Call for Nominations for IACS President-Elect and Some Council Members

The term of Dr. Grant Pierce as IACS-President will end after the IACS-North American Section meeting in Las Vegas during September 18-20, 2025. Thereafter, Dr. András Varró will assume the Office of IACS-President. Furthermore, the term of 3 to 4 IACS-Council Members will be coming to an end in September, 2025. Accordingly, nominations from Members and Fellows of the Academy are requested for the following officer and some council member positions for election by the Academy:

1. IACS President-Elect
2. Three or four IACS Council Members

Nominations should include name, affiliation, address and contact information (both email and telephone). Please send nominations by July 15, 2025 to Dr. Naranjan S. Dhalla, Executive Director, IACS, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, Canada (Email: nsdhalla@sbrc.ca).

Call for Nominations for IACS- North American Section President-Elect and Some Council Members

The term of Dr. Michael Czubryt, President of the IACS-North American Section is coming to an end in September, 2025. Thereafter Dr. Buddha Dawn will be assuming the position of President of the IACS-North American Section. In addition, the terms of some Council Members of the Section will also expire. Accordingly, nominations for the following positions are invited for election by the Academy:

1. IACS-North America Section President-Elect
2. Three or four IACS North American Section Council Members

Nominations should include name, affiliation, address and contact information (both email and telephone). Please send nominations by July 15, 2025 to Dr. Devendra Agrawal, Secretary General, IACS-North American Section, Western University of Health Sciences, Pomona, USA (Email: dagrawal@westernu.edu).

Call for Nominations for Some Council Members for IACS- European Section

The term of 3 to 4 Council Members of the IACS-European Section will be coming to an end in November, 2025. Accordingly, nominations from Members and Fellows of the European Section are requested for the following council members for election by the Academy:

Three or four IACS-European Section Council Members

Nominations should include name, affiliation, address and contact information (both email and telephone). Please send nominations by July 15, 2025 to Dr. István Baczkó, Secretary General, IACS-European Section, University of Szeged, Hungary. (Email: baczko.istvan@med.u-szeged.hu).

What's New in the Canadian Journal of Physiology and Pharmacology

What's New in the *Canadian Journal of Physiology and Pharmacology*

The *Canadian Journal of Physiology and Pharmacology* is looking for clinician–researchers to join its Editorial Board!

The journal is growing to include more clinical content, and we are excited to invite **clinician–researchers** to join us in this endeavor.

If you are a clinician–researcher who works in cardiovascular, muscular, respiratory, hepatic, or renal health, oncology, neurology, metabolism, immunology, or psychopharmacology and pharmacokinetics, and you are interested in contributing as an Associate Editor or peer reviewer for the journal, we would be thrilled to hear from you!

Associate Editors manage peer review and make decision recommendations to Section Editors based on reviewer reports and their own assessment of assigned manuscripts (<12 per year). Associate Editors also collaborate with the journal team to develop and promote the journal.

Please send expressions of interest—including your CV and a brief description of your qualifications, area(s) of expertise, and any relevant peer review or editorial experience—to engagement@cdnsciencepub.com.

Canadian Journal of Physiology and Pharmacology - Editor's Choice

The following are recent selections from each journal month by the Editor-in-Chief, Dr Lorrie Kirshenbaum. Congratulations to everyone whose paper was selected!

- April: Effects of acute aerobic exercise on skeletal muscle and liver glucose metabolism in male rodents with type 1 diabetes
  https://doi.org/10.1139/cjpp-2024-0226
- May: Systematic review of Health Canada approved clinical therapeutic trials for the treatment or prevention of coronavirus disease 2019 (COVID-19)
  https://doi.org/10.1139/cjpp-2024-0055
- June: Epicardial adipose tissue as target of the incretin-based therapies in cardio-metabolic pathologies: a narrative review
  https://doi.org/10.1139/cjpp-2024-0384

Canadian Journal of **Physiology and Pharmacology**

Canadian **Science** Publishing

Canadian Science Publishing
123 Slater Street, Suite 610
Ottawa, Ontario K1P 5H2
t 613-656-9846 f 613-656-983

Partnering Journals of the IACS



Canadian Journal of Physiology and Pharmacology
Impact Factor: 1.7

Editor-in-Chief:
Dr. Lorrie A. Kirshenbaum

Editorial Office:
Canadian Science Publisher
1840 Woodward Drive, Suite 1
Ottawa, ON K2C 0P7 Canada
Email: cjpp@cdnsciencepub.com



The Journal of Cardiovascular Aging
An Open Access Journal

Honorary Editor-in-Chief:
Dr. Dayi Hu

Editorial Office:
OAE Publishing Inc.
245 E Main Street Ste 107,
Alhambra, CA 91801, USA
Email: editorialoffice
@cardiovascularaging.com;
cardiovascularaging@gmail.com

American Journal of Cardiovascular Drugs
Impact Factor: 2.8; CiteScore: 6.7

Editor-in-Chief:
Dr. Amitabh Prakash

Editorial Office:
Adis, Springer Healthcare
74 Taharoto Road, Takapuna
Auckland, 0622, New Zealand
Email: amitabh.prakash@springer.com



Heart Failure Reviews
Impact Factor: 4.5

Editor-in-Chief:
Dr. Andrew P. Ambrosy

Editorial Office:
Kaiser Permanente San Francisco Medical Center and Kaiser Permanente Northern California Division of Research, USA
Email: Lovely.Obico@springernature.com

IACS partnering journals:

1. *Canadian Journal of Physiology and Pharmacology*
2. *The Journal of Cardiovascular Aging*
3. *American Journal of Cardiovascular Drugs*
4. *Heart Failure Reviews*

Readers are encouraged to submit original research articles and reviews to these partnering journals.